Author Index to Volume 44

Abdollohian A. See Boutros N
Adak B. See Ağargün MY
Adler LE. See Ross RG
Agam G. See Shimon H
Ağargün MY, Tekeoğlu I, Kara H, Adak B, Ercan M. Hypnotizability, pain threshold, and dissociative experiences, 69
Aghajanian GK. See Marek GJ
Ahn J. See Goi VL
Ahrén B. See Olsson T
Akefeldt A, Ekman R, Gillberg C, Mansson J-E. Cerebrospinal fluid monoamines in Prader-Willi syndrome, 1321
Alain C, Hargrave H, Woods DL. Processing of auditory stimuli during visual attention in patients with schizophrenia, 1151
Albala BJ. See Rush AJ
Alda M, Grof P, Grof E. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium, 361
Alexander JT. See Leibowitz SF
Allen RH. See Susser E
Alpert NM. See O'Driscoll GA
Al-Shabbout M. See Kaufman J
Amadeo S. See Savoye C
Amdur R. See Casada JH
Amir I. See Rabey JM
Amir M. See Grisaru N
Amore M. See Berardi D
Anderson GM
See Martin A
See Pfeffer CR
Andreasen NC. See Tibbo P
Andreason P. See Nordahl TE
Apparsundaram S. See Blakely RD
Armitage A. See Rush AJ
Arndt S
See Perry PJ
See Tibbo P
Arolt V, Teichert H-M, Steege D, Lencer R, Heide W. Distinguishing schizophrenic patients from healthy controls by quantitative measurement of eye movement disorders, 448
Ascroft RC. See Rosenbaum JF
Ashton CH. See Dahabra S
Atack JR, Levine J, Belmaker RH. Cerebrospinal fluid inositol monophosphatase: elevated activity in depression and neuroleptic-treated schizophrenia, 433
Aubin H-J, Laureaux C, Zerah F, Tilikete S, Vernier F, Vallat B, Barrucand D. Joint influence of alcohol, tobacco, and coffee on biological markers of heavy drinking in alcoholics, 638

Bäckström T. See Sundström I
Bahrainian M. See Dahabra S
Baker DG. See Geracioti TD Jr
Baker GB. See Rotzinger S
Bakker A. See Veltman DJ
Baldwin RM. See Malison RT
Ballenger JC. Translational implications of the amygdala-stria terminalis model for the clinical anxiety disorders, 1204
Bardgett ME. See Csermansky JG
Barkley RA. See King JA
Barrett S. See King JA
Barrucand D. See Aubin H-J
Bartzokis G. See Wirshing DA
Basun H. See Forsell Y
Bates J. See Umbricht D, 716
Baumann MH, Rothman RB. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans, 578
Bellavance F. See Le Mellédo J-M
Belmaker RH
See Atack JR
See Shimon H
Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives, 88
Benkelfat C. See Nordahl TE
Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M. Clinical and pharmacological risk factors for neuroleptic malignant syndrome: a case-control study, 748
Berman R. See Malison RT
Bernardo M. See Parellada E
Berrettini W. Cloning the human gamma-aminobutyric acid B receptor gene: multiple windows of opportunity in biological psychiatry, 657-ed
Berrios GE. See Sierra M
Bertolino A. See Callicott JH
Bever KA. See Perry PJ
Bhatti T. See Seifritz E
Bichet DG. See Le Mellédo J-M
Biederman J
See Faraone SV
See Seidman LJ
Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol use and dependence?, 269
Bilder R. See Chakos MH
Bilker W. See Swanson CL Jr
Birmaher B. See Kaufman J
Blakeley JE. See Gurguis GNM
Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transport proteins, 169
Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses, 313
Bloch M. See Shalev A
Blomhoff S, Reinvang I, Malt UF. Event-related potentials to stimuli with emotional impact in posttraumatic stress disorder patients, 1045
Bogdan A. See Millet B
Boland RJ. See Keller MB
Bonet P. See Corominas A
Bonne O. See Shalev A
Bourdel M-C. See Millet B
Boutros N, Fristad M, Abdollohian A. The fourteen and six positive spikes and attention-deficit hyperactivity disorder, 298

© 1998 Society of Biological Psychiatry

0006-3223/98/$19.00

Bowden CL
See Goodnick PJ
See Goi VL
Bradley MM. See Lang PJ
Bradwejn J. See Le Mellédo J-M
Braff D. See Perry W
Brawman-Mintzer O. See Mintzer J
Brent D. See Kaufman J
Brin FB. See Coburn KL
Britton PG. See Dahabra S
Brown A. See Piggott MA
Brown AS. See Susser E
Broyer M. See Lestra C
Bruce AB. See Geracioti TD Jr
Bulik C, Sullivan PF, Kendler KS. Heritability of binge-eating and broadly defined bulimia nervosa, 1210
Bury A. See Roy PD
Bush G. See Whalen PJ

Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJP, Frank JA, Weinberger DR. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype, 941
Carl JR. See Sweeney JA
Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome, 378
Carpenter L. See Malison RT
Carson SW. See Sallee FR, 220
Casada JH, Amdur R, Larsen R, Liberzon I. Psychophysiologic responsivity in posttraumatic stress disorder: generalized hyperresponsiveness versus trauma specificity, 1037
Casper R. Serotinin, a major player in the regulation of feeding and affect, 795-ed
Cassuto Y. See Cohen H
Castellanos JM. See Catalán R
Catafau AM. See Parellada E
Catalán R, Gallart JM, Castellanos JM, Galard R. Plasma corticotropin-releasing factor in depressive disorders, 15
Catarineu S. See Parellada E
Chakos M. See Lieberman JA
Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA. Striatal enlargement in rats chronically treated with neuroleptic, 675
Chamba G. See Lestra C
Charney DS
See Innis RB
See Malison RT
See Rosenheck R
See Weinberger D
Chen S. See Tsai G
Choi J. See Goi VL
Chung L-C. See Tsai G
Claffey E. See Mynett-Johnson
Clark LM, McDonald WM, Welsh-Bohmer KA, Siegler IC, Dawson DV, Tupler LA, Krishnan KRR. Magnetic resonance imaging correlates of depression in early- and late-onset Alzheimer's disease, 592
Cleare AJ, Murray RM, O'Keane V. Assessment of serotonergic function in major depression using *d*-fenfluramine: relation to clinical variables and antidepressant response, 555
Coburn KL, Shillcutt SD, Tucker KA, Estes KM, Brin FB, Merai P, Moore NC. P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication, 466
Cohen H. See Grisaru N
Cohen H, Kaplan Z, Kotler M. Inhibition of anxiety in rats by antisense to cholecystokinin precursor protein, 915
Cohen H, Kotler M, Matar MA, Kaplan Z, Loewenthal U, Miodownik H, Cassuto Y. Analysis of heart rate variability in posttraumatic stress disorder patients in response to a trauma-related reminder, 1054
Cohen LS. See Joffe H
Cohen RM. See Nordahl TE
Collier DA. See Li T
Combs MD. See Perry PJ
Connor KM, Davidson JRT. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives, 1286
Cooper TB. See Devanand DP
Coplan JD. See Kent JM
Coplan JD, Lydiard RB. Brain circuits in panic disorder, 1264
Corder EH. See Forsell Y
Corominas A, Bonet P, Nieto E. Recurrent brief depression successfully treated with lithium, 927
Costa E. See Guidotti A
Court JA. See Piggott MA
Coutts RT. See Rotzinger S
Cowley D. See Peskind ER
Coyle JT. See Tsai G, 667
Cramer J. See Rosenheck R
Crayton J. See Rosenheck R
Császár A. See Zsurka G
Csermansky CA. See Csermansky JG
Csermansky JG, Csermansky CA, Kogelman L, Montgomery E-M, Bardgett ME. Progressive neurodegenerations after intracerebroventricular kainic acid administration in rats: implications for schizophrenia?, 1143
Cuesta MJ. See Peralta V
Curtin F, Schulz P. Multiple correlations and Bonferroni's correction, 775
Cuthbert BN. See Lang PJ

Dahabra S, Ashton CH, Bahrainian M, Britton PG, Ferrier IN, McAllister VA, Marsh VR, Moore PM. Structural and functional abnormalities in elderly patients clinically recovered from early- and late-onset depression, 34
Dahl RE. See Kaufman J
Dalery J. See Lestra C
d'Amato T. See Lestra C
Davidson JRT. See Connor KM
Davidson M. See Shimon H
Davis JM. See Sharama RP
Davis M
Are different parts of the extended amygdala involved in fear vs. anxiety?, 1239
See Grillon C
Dawson DV. See Clark LM
Deakin JFW. See Simpson MDC
Deas-Nesmith D. See Sallee FR
DeBattista C, Sofuoglu M, Schatzberg AF. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs, 341
de Bruin WI. See Ho Pian KL
DeFelice LJ. See Blakely RD
Dell'Atti M. See Berardi D
de Montigny C. See Blier P
den Boer JA. See Ho Pian KL
Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. See Rosenheck R

Devanand DP, Lisanby S, Lo E-S, Fitzsimons L, Cooper TB, Halbreich U, Sackeim HA. Effects of electroconvulsive therapy on plasma vasopressin and oxytocin, 610
DeVane CL. See Goodnick PJ
Dierker L. See Grillon C
di Michele F. See Rupprecht R
Dominguez RA. See Goodnick PJ
D'Souza C. See Krystal JH
Duman RS. Novel therapeutic approaches beyond the serotonin receptor, 324
Dumont M. See Guillemette J
Duncan G. See Lieberman JA
Dwivedi Y. See Pandey GN

Ebert U. See Koch M
Egan MF. See Callicott JH
Ehlers CL. See Orozco S
Ekhator NN. See Geracioti TD Jr
Ekman R. See Akefeldt A
Elkis H. See Friedman L
El-Mallakh RS. See Rose AM
Engdahl BE. See Hurwitz TD
Ercan M. See Ağargün MY
Erhart SM. See Wirshing DA
Erman MK. See Rush AJ
Estes KM. See Coburn KL

Fairbairn A. See Piggott MA
Fang J. See Rotzinger S
Faraone SV
See Biederman J
See Seidman LJ
Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder, 951
Fava M. See Rosenbaum JF
Felger T. See Perry W
Fensterheim L. See Pfeffer CR
Ferrier IN. See Dahabra S
Fischer P. See Tauscher J
Fitzsimons L. See Devanand DP
Fleming JB. See Rush AJ
Forsell Y, Basun H, Corder EH, Lannfelt L, Winblad B. Psychotic symptoms and apolipoprotein E genotypes in an elderly population, 139
Frank JA. See Callicott JH
Freedman R
Biological phenotypes in the genetics of schizophrenia, 939-ed
See Griffith JM
See Ross RG
Friedhoff AJ. See Rosengarten H
Friedman BH. See Thayer JF
Friedman L, Wiechers IR, Elkis H. Global structural brain abnormalities in mood disorders: evidence from a meta-analysis versus a traditional review, 932-corr
Fristad M. See Boutros N
Fryer AJ. Current approaches to etiology and pathophysiology of specific phobia, 1295
Fujisaki Y. See Inoue K

Gagnon M, Layton S, Messier C. Sexual dysfunction and selective serotonin reuptake inhibitors, 374-corr
Galard R. See Catalán R
Gallart JM. See Catalán R
Galli A. See Blakely RD
Garver D. See Griffith JM
Gendall K. See Kaye W
George DT. See Hibbeln J, 235
Geracioti TD Jr, Keck PE Jr, Ekhator NN, West SA, Baker DG, Hill KK, Bruce AB, Wortman MD. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid, 228
Gerber DK. See Yehuda R
Ghaemmaghami C. See Lestra C
Gheysen F. See Savoye C
Gillberg C. See Akefeldt A
Gillin JC
See Rush AJ
See Seifritz E
Goi VL, Choi J, Ahn J, Bowlus CL, Raha-Chowdhury R, Gruen JR. Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization, 659
Golden RN. Selective serotonin reuptake inhibitor elimination half-lives: the long and short of it, 75-ed
González-Monclús E. See Parellada E
Goodnick PJ, Dominguez RA, DeVane CL, Bowden CL. Bupropion slow-release response in depression: diagnosis and biochemistry, 629
Gorman JM. See Kent JM
Greden JF. Serotonin: how much we have learned! So much to discover..., 309-ed
Green JF, King DJ. The effects of chlorpromazine and lorazepam on abnormal antisaccade and no-saccade distractibility, 709
Green MF. See Kern RS
Grier A. See Tsai G
Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
Grillon C, Dierker L, Merikangas KR. Fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
Grillon C, Morgan CA III, Davis M, Southwick SM. Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder, 1027
Grisaru N, Amir M, Cohen H, Kaplan Z. Effect of transcranial magnetic stimulation in posttraumatic stress disorder: a preliminary study, 52
Grof E. See Alda M
Grof P. See Alda M
Gruen JR. See Goi VL
Guidotti A, Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3α, 5α-tetrahydroprogesterone (allopregnenolone) availability?, 865
Guillemette J, Hébert M, Paquet J, Dumont M. Natural bright light exposure in the summer and winter in subjects with and without complaints of seasonal mood variations, 622
Gullion CM, Rush AJ. Toward a generalizable model of symptoms in major depressive disorder, 959
Gur RC. See Swanson CL Jr
Gur RE. See Swanson CL Jr
Gurguis GNM, Yonkers KA, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet α_2 receptors: G_i coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity, 600

Haas GL. See Sweeney JA
Halbreich U. See Devanand DP
Han J-S. See Ulett GA
Han S. See Ulett GA
Hanchett JM. See Martin A,
Hantouche E. See Millet B

Hargrave H. See Alain C
Haroutunian V. See Shimon H
Harris JG. See Ross RG
Hatch M. See Seidman LJ
Hattori M. See Sasaki T
Heath AC. Binge-eating and bulimia: potential insights into etiology and pathophysiology through genetic epidemiologic studies, 1208
Hébert M. See Guillemette J
Heide W. See Arolt V
Hen R. See Stark KL
Herman MM. See Rose AM
Hermann B. See Rupprecht R
Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr. Essentially fatty acids predict metabolites of serotinin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics, 235
Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, Vaughan MR, Rawlings R, Salem N Jr. A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids, 243
Hicks PB. See Wadenburg M-LG
Higashima M, Urata K, Kawasaki Y, Maeda Y, Sakai N, Mizukoshi C, Nagasawa T, Kamiya T, Yamaguchi N, Koshino Y. P300 and the thought disorder factor extracted by factor-analytic procedures in schizophrenia, 115
Hill KK. See Geracioti TD Jr
Hirayasu Y. See Potts GF
Hirose T. See Sasaki T
Hollander E. See Simeon D
Holsboer F. See Rupprecht R
Holzbach R, Jahn H, Pajonk F-G, Mähne C. Suicide attempts with mirtazapine overdose without complications, 925
Holzman PS. See O'Driscoll GA
Hong C-J. See Hwu H-G
Hoog SL. See Rosenbaum JF
Ho Pian KL, Westenberg HGM, den Boer JA, de Bruin WI, van Rijk PP. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls, 367
Hubain P. See Stefos G
Hübner G. See Volz H-P
Humaran TJ. See Kegeles LS
Hurwitz TD, Mahowald MW, Kuskowski M, Engdahl BE. Polysomnographic sleep is not clinically impaired in Vietnam combat veterans with chronic posttraumatic stress disorder, 1066
Hwu H-G, Hong C-J, Lee Y-L, Lee P-C, Lee SFC. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia, 483
Hyman S. Brain neurocircuitry of animal and fear: implications for clinical research and practice, 1201

Innis RB
See Malison RT
See Staley JK
Innis RB, Nestler EJ, Charney DS. New research series, 145-ed
Inoue K, Kiriike N, Okuno M, Fujisaki Y, Kurioka M, Iwasaki S, Yamagami S. Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction—a rat model of binge eating, 1329
Insel TR, Winslow JT. Serotonin and neuropeptides in affiliative behaviors, 207
Ishiguro T. See Nisijima K
Iwasaki S. See Inoue K

Jahn H. See Holzbach R
Janicak PG
See Pandey GN
See Sharama RP
Janka Z. See Zsurka G
Jatlow P. See McCantz-Katz EF
Javaid JI. See Sharama RP
Javitt D. See Umbricht D
Jenike MA. See Whalen PJ
Jensen CF. See Peskind ER
Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?, 798
Johnson M. See Piggott MA
Juhász A. See Zsurka G

Kaiser WA. See Volz H-P
Kakuma T. See Pfeffer CR
Kálmán J. See Zsurka G
Kamiya T. See Higashima M
Kane J. See Umbricht D
Kaplan Z
See Cohen H
See Grisaru N
Kaplita SB. See Rush AJ
Kara H. See Ağargün MY
Kasper S. See Tauscher J
Kato T. See Sasaki T
Katz N. See Lavie P
Kaufman J, Birmaher B, Perel J, Dahl RE, Still S, Brent D, Trubnick L, Al-Shabbout M, Ryan ND. Serotonergic functioning in depressed abused children: clinical and familial correlates, 973
Kawasaki Y. See Higashima M
Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa, 825
Kaye WH. See Martin A
Keck PE Jr
See Berardi D
See Caroff SN
See Geracioti TD Jr
See Sax KW
Kegeles LS, Humaran TJ, Mann JJ. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy, 382
Keller, MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression, 348
Kelley ME. See Tsai G
Kelsoe JR. See Seifritz E
Kendler KS. See Bulik C
Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety, 812
Kerkhofs M. See Stefos G
Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients, 726
Keshavan MS. See Sweeney JA
Khait V. See Pfeffer CR
King DJ. See Green JF
King JA, Barkley RA, Barrett S. Attention-deficit hyperactivity disorder and the stress response, 72

Kiriike N. See Inoue K
Kleinman JE. See Rose AM
Klonowski E. See Susser E
Ko H-C. See Shiah I-S
Koch M, Ebert U. Deficient sensorimotor gating follows seizures in amygdala-kindled rats, 290
Kogelman L. See Csermansky JG
Koran LM. See Sallee FR
Korczyn AD. See Rabey JM
Koshino Y. See Higashima M
Kosten TR. See McCantz-Katz EF
Koszycki D. See Le Mellédo J-M
Kotler M. See Cohen H, 915
Kraus JE. See Lieberman JA
Krebs WB. See Rosenbaum JF
Kreitschmann-Andermahr I. See Volz H-P
Krieg J-C. See Lauer CJ
Krishnan KRR. See Clark LM
Kroeze WK, Roth BL. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis, 1128
Krystal JH, D'Souza C. D-Serine and the therapeutic challenge posed by the *N*-methyl-D-aspartate antagonist model of schizophrenia, 1075
Kumari R. See Pandey GN
Kunugi H. See Sasaki T
Kurioka M. See Inoue K
Kusakabe Y. See Nisijima K
Kuskowski M. See Hurwitz TD
Kwok EW. See Benes FM

Lang PJ, Bradley MM, Cuthbert BN. Emotion, motivation, and anxiety: brain mechanisms and psychophysiology, 1248
Lange N. See Tsai G
Langevin R. See Roy PD
Langheim FJP. See Callicott JH
Lannfelt L. See Forsell Y
Larsen R. See Casada JH
Lauer CJ, Krieg J-C. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression, 121
Laureaux C. See Aubin H-J
Laurent C. See Savoye C
Lavie P, Katz N, Pillar G, Zinger Y. Elevated awaking thresholds during sleep: characteristics of chronic war-related posttraumatic stress disorder patients, 1060
Lawson W. See Rosenheck R
Layton S. See Gagnon M
Leboyer M. See Savoye C
Leckman JF
See Martin A
See Peterson BS
LeDoux JE. Fear and the brain: where have we been, and where are we going?, 1229
Lee JWY. Serum iron in catatonia and neuroleptic malignant syndrome, 499
Lee K. See Chakos MH
Lee P-C. See Hwu H-G
Lee SFC. See Hwu H-G
Lee Y-L. See Hwu H-G
Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight, 851
Lejeune J. See Savoye C
Le Mellédo J-M, Bradwejn J, Koszycki D, Bichet DG, Bellavance F. The role of the β-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms, 364
Lencer R. See Arolt V
Lesch K-P, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?, 179
Lestra C, d'Amato T, Ghaemmaghami C, Perret-Liaudet A, Broyer M, Renaud B, Dalery J, Chamba G. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome, 274
Levengood RA. See Yehuda R
Levine J. See Atack JR
Levy DL. See O'Driscoll GA
Li R. See Rose AM
Li T, Vallada HP, Liu X, Xie T, Tang X, Zhao J, O'Donovan MC, Murray RM, Sham PC, Collier DA. Analysis of CAG/CTG repeat size in Chinese subjects eith schizophrenia and bipolar affective disorder using the repeat expansion detection method, 1160
Liberzon I. See Casada JH
Lieberman J
See Chakos MH
See Umbricht D
Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia, 1099
Lindenbaum J. See Susser E
Linkowski P. See Stefos G
Linnoila M. See Hibbeln J
Lisanby S. See Devanand DP
Liu X. See Li T
Lloyd S. See Piggott MA
Lo E-S. See Devanand DP
Loewenthal U. See Cohen H
Lomeña F. See Parellada E
Lu R-B. See Shiah I-S
Lucki I. The spectrum of behaviors influenced by serotonin, 151
Luna B. See Sweeney JA
Lydiard RB. See Coplan JD

Maeda Y. See Higashima M
Maher BA, Manschreck TC, Yurgelun-Todd DA, Tsuang MT. Hemispheric asymmetry of frontal and temporal gray matter and age of onset in schizophrenia, 413
Mähne C. See Holzbach R
Mahowald MW. See Hurwitz TD
Mailman RB. See Lieberman JA
Malison RT. See Staley JK
Malison RT, Price LH, Berman R, Van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2B-carbomethoxy-3B-(4-iodephenyl)tropane and single photon emission computed tomography, 1090
Mallet J. See Savoye C
Malt UF. See Blomhoff S
Manley P. See Mynett-Johnson
Mann JJ
The role of in vivo neurotransmitter system imaging studies in understanding major depression, 1077
See Kegeles LS
See Soares JC
Mann SC. See Caroff SN
Manschreck TC. See Maher BA
Mansson J-E. See Akefeldt A
Marder SR
See Kern RS
See Wirshing DA
Marek GJ, Aghajanian GK. The

electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis, 1118
Marsh J. See Meyer JM
Marsh VR. See Dahabra S
Marshall BD Jr. See Kern RS
Marshall EF. See Piggott MA
Martin A, State M, Anderson GM, Kaye WH, Hanchett JM, McConaha CW, North WG, Leckman JF. Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report, 1349
Martin DC. See Peskind ER
Matar MA. See Cohen H
Mattay VS. See Callicott JH
Matthysse SW. See O'Driscoll GA
McAllister VA. See Dahabra S
McBride PA. See Pfeffer CR
McCantz-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potenyially more toxic than use of either alone—a multiple-dose study, 250
McCarley RW. See Potts GF
McConaha CW. See Martin A
McCormack J. See Mynett-Johnson
McDonald WM. See Clark LM
McElroy SL. See Sax KW
McFarlane AC. See Yehuda R
McGurk S. See Kern RS
McInerney SC. See Whalen PJ
McKeith IG. See Piggott MA
McKeon P. See Mynett-Johnson
McNally RJ. See Whalen PJ
McQuade RD. See Rush AJ
Meeks A. See Mintzer J
Mellett BJ. See Rose AM
Melrose HL. See Piggott MA
Mendlewicz J. See Stefos G
Merai P. See Coburn KL
Merikangas KR. See Grillon C
Messier C. See Gagnon M
Meyer JM, Marsh J, Simpson G. Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient, 791
Mick E. See Biederman J
Millet B, Touitou Y, Poirier M-F, Bourdel M-C, Hantouche E, Bogdan A, Olié J-P. Plasma melatonin and cortisol in patients with obsessive compulsive disorder: relationship with axillary temperature, physical activity, and clinical symptoms, 874
Mintz J. See Kern RS
Mintzer J, Brawman-Mintzer O, Mirski DF, Unger R, Nietert P, Meeks A, Sampson R. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia, 918
Miodownik H. See Cohen H
Mirski DF. See Mintzer J
Mizukoshi C. See Higashima M
Moldofsky H. See Rush AJ
Montgomery E-M. See Csermansky JG
Montplaisir J. See Rush AJ
Moore NC. See Coburn KL
Moore PM. See Dahabra S
Morgan CA III. See Grillon C
Mossner R. See Lesch K-P
Murphy V. See Mynett-Johnson
Murray RM
See Cleare AJ
See Li T
Mynett-Johnson L, Murphy V, McCormack J, Shields DC, Claffey E, Manley P, McKeon P. Evidence for an allelic association between bipolar disorder and a Na^+, K^+ adenosine triphosphatase alpha subunit gene (ATP1A3), 47

Nagai M. See Ohara Koichi
Nagasawa T. See Higashima M
Nanko S. See Sasaki T
Näsman B. See Olsson T
Nemeroff CB.
Psychopharmacology of affective disorders in the 21st century, 517
See Malison RT
Nestler EJ.
Antidepressant treatments in the 21st century, 526
See Innis RB
Neumeister A. See Tauscher J
Nichols DE. See Lieberman JA
Nietert P. See Mintzer J
Nieto E. See Corominas A
Nisijima K, Kusakabe Y, Ohtuka K, Ishiguro T. Addition of carbamazepine to long-term treatment with neuroleptics may induced neuroleptic malignant syndrome, 930
Nopoulos P. See Tibbo P
Nordahl TE, Stein MB, Benkelfat C, Semple WE, Andreason P, Zametkin A, Uhde TW, Cohen RM. Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorder, 998
North WG. See Martin A
Novak G. See Umbricht D

Oberman Z. See Rabey JM
Odom AM. See Sallee FR
O'Donnell BF. See Potts GF
O'Donovan MC. See Li T
O'Driscoll GA, Strakowski SM, Alpert NM, Matthysse SW, Rauch SL, Levy DL, Holzman PS. Differences in cerebral activation during smooth pursuit and saccadic eye movements using positron-emission tomography, 685
Ohara Kenshiro. See Ohara Koichi
Ohara Koichi, Nagai M, Tsukamoto T, Tani K, Suzuki Y, Ohara K. Functional polymorphism in the serotonin transport promoter at the SLC6A4 locus and mood disorders, 550
Ohtuka K. See Nisijima K
O'Keane V. See Cleare AJ
Okuno M. See Inoue K
Olié J-P. See Millet B
Olincy A. See Ross RG
Olsson T, Näsman B, Rasmuson S, Ahrén B. Dual relation between leptin and cortisol in humans is disturbed in Alzheimer's disease, 374-corr
O'Neill JE. See Griffith JM
Oosting RS. See Stark KL
Orozco S, Ehlers CL. Gender differences in electrophysiologcal responses to facial stimuli, 281
Owens MJ. See Malison RT

Pajonk F-G. See Holzbach R
Pallanti S. See Sallee FR
Pandey GN, Dwivedi Y, Kumari R, Janicak PG. Protein kinase C in platelets of depressed patients, 909
Paquet J. See Guillemette J
Parellada E, Catafau AM, Bernardo M, Lomeña F, Catarineu S, González-Monclús E. The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients, 787
Pascualy M. See Peskind ER
Pasini A. See Rupprecht R

Pelton GH. See Malison RT
Peralta V, Cuesta MJ. Factor structure and clinical validity of competing models of positive symptoms in schizophrenia, 107
Perel J. See Kaufman J
Peri T. See Shalev A
Perret-Liaudet A. See Lestra C
Perry EK. See Piggott MA
Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nosogram, 733
Perry RH. See Piggott MA
Perry W, Felger T, Braff D. The relationship between skin conductance hyporesponsivity and perseverations in schizophrenia patients, 459
Peskind ER, Jensen CF, Pascualy M, Tsuang D, Cowley D, Martin DC, Wilkinson CW, Raskind MA. Sodium lactate and hypertonic sodium chloride induce panic incidence, panic symptoms, and hypernatremia in panic disorder, 1007
Peterson BS, Leckman JF. The temporal dynamics of tics in Gilles de la Tourette syndrome, 1337
Petty F. See Griffith JM
Petty RG. See Swanson CL Jr
Pfeffer CR, McBride PA, Anderson GM, Kakuma T, Fensterheim L, Khait V. Peripheral serotonin measures in prepubertal psychiatric inpatients and normal children: associations with suicidal behavior and its risk factors, 568
Phan SP. See Gurguis GNM
Pierre JM. See Wirshing DA
Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, Court JA, Lloyd S, Fairbairn A, Brown A, Thompson P, Perry RH. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease, 765
Pillar G. See Lavie P
Poirier M-F. See Millet B
Pollack S. See Umbricht D
Post RM, Weiss SRB. Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression, 193
Potts GF, Hirayasu Y, O'Donnell BF, Shenton ME, McCarley RW. High-density recording and topographic analysis of the auditory oddball event-related potential in patients with schizophrenia, 982
Price LH. See Malison RT

Qian Y. See Blakely RD

Rabey JM, Amir I, Treves TA, Oberman Z, Korczyn AD. Dopamine uptake by platelet storage granules in first degree relatives of Tourette's syndrome patients, 1166
Radant A. See Ross RG
Ragan PW. See Hibbeln J
Raha-Chowdhury R. See Goi VL
Rajeevan N. See Malison RT
Ramamoorthy S. See Blakely RD
Rao Jagadeesh S, Subhash MN. Effect of antidepressants on intracellular Ca^{++} mobilization in human frontal cortex, 617
Rapaport MH. See Seifritz E
Rappelsberger P. See Tauscher J
Raskind MA. See Peskind ER
Raskó I. See Zsurka G
Rasmuson S. See Olsson T
Rauch SL
See O'Driscoll GA
See Whalen PJ
Rawlings R. See Hibbeln J
Reinvang I. See Blomhoff S
Renaud B. See Lestra C
Reynolds CF III. What do antidepressant effects on sleep tells us about pathways to treatment response?, 1-ed
Richter JT. See Wadenburg M-LG
Roca CA. See Rubinow DR
Romeo E. See Rupprecht R
Rose AM, Mellett BJ, Valdes R Jr, Kleinman JE, Herman MM, Li R, El-Mallakh RS. Alpha2 isoform of the Na,K-adenosine triphosphatase is reduced in temporal cortex of bipolar individuals, 892
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial, 77
Rosengarten H, Friedhoff AJ. A phosphoinositide-linked dopamine D1 receptor mediates repetitive jaw movements in rats, 1178
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Predictors of Differential Response to Clozapine and Haloperidol, 475
Ross RG, Olincy A, Harris JG, Radant A, Adler LE, Freedman R. Anticipatory saccades during smooth pursuit eye movements and familial transmission of schizophrenia, 690
Rössger G. See Volz H-P
Rossy LA. See Thayer JF
Roth BL. See Kroeze WK
Rothman RB. See Baumann MH
Rotzinger S, Fang J, Coutts RT, Baker GB. Human CP2D6 and metabolism of m-chlorophenylpiperizine, 1185
Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics, 633
Roy PD, Zipursky RB, Saint-Cyr JA, Bury A, Langevin R, Seeman MV. Temporal horn enlargement is present in schizophrenia and bipolar disorder, 418
Rubenstein JLR. Development of serotonergic neurons and their projections, 145
Rubinow DR. Markku Linnoila (In Memoriam), 307
Rubinow DR, Schmidt PJ, Roca CA. Estrogen–serotonin interactions: implications for affective regulation, 839
Rupprecht R, Ströhle A, Hermann B, di Michele F, Spalletta G, Pasini A, Holsboer F, Romeo E. Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers, 912
Rush AJ
See Gullion CM
See Gurguis GNM
Rush AJ, Armitage A, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, Vogel GW, Kaplita SB, Fleming JB, Montplaisir J, Erman MK,

Albala BJ, McQuade RD. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder, 3
Ryan ND. See Kaufman J
Ryan ND, Varma D. Child and adolescent mood disorder—experience with serotinin-based therapies, 336
Rzanny R. See Volz H-P

Sackeim HA. See Devanand DP
Saint-Cyr JA. See Roy PD
Sakai N. See Higashima M
Sakai T. See Sasaki T
Salem N Jr. See Hibbeln J
Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks, 220
Sallee FR, Vrindavanam NS, Deas-Nesmith D, Odom AM, Carson SW, Sethuraman G. Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response, 562
Sampson R. See Mintzer J
Sanacora G. See Malison RT
Sasaki T, Hattori M, Sakai T, Kato T, Kunugi H, Hirose T, Nanko S. The monoamine oxidase-A gene and major psychosis in Japanese subjects, 922
Sauer H. See Volz H-P
Savoye C, Laurent C, Amadeo S, Gheysen F, Leboyer M, Lejeune J, Zarifian E, Mallet J. No association between dopamine D_1, D_2 and D_3 receptor genes and manic-depressive illness, 644
Sax KW. See Strakowski SM
Sax KW, Strakowski SM. Enhanced behavioral response to repeated d-amphetamine and personality traits in humans, 1192
Sax KW, Strakowski SM, Keck PE Jr, McElroy SL, West SA, Stanton SP. Symptom correlates of attentional improvement following hospitalization for a first episode of affective psychosis, 784
Schatzberg AF. See DeBattista C
Schmeidler J. See Yehuda R
Schmidt PJ. See Rubinow DR
Schooler NR. See Sweeney JA
Schroeter S. See Blakely RD
Schulz P. See Curtin F
Seeman MV. See Roy PD
Seibyl JP. See Malison RT
Seidman LJ, Biederman J, Weber W, Hatch M, Faraone SV. Neuropsychological function in adults with attention-deficit hyperactivity disorder, 260
Seifritz E, Gillin JC, Rapaport MH, Kelsoe JR, Bhatti T, Stahl SM. Sleep electroencephalographic response to muscarinic and serotonin$_{1A}$ receptor probes in patients with major depression and in normal controls, 21
Semple WE. See Nordahl TE
Sethuraman G. See Sallee FR
Shalev AY. See Yehuda R
Shalev AY, Bloch M, Peri T, Bonne O. Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder, 64
Sham PC. See Li T
Sharma RP, Javaid JI, Davis JM, Janicak PG. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period, 488
Shenton ME. See Potts GF
Shiah I-S, Ko H-C, Lu R-B. The lower limits of dexamethasone window in Chinese depressives, 648
Shields DC. See Mynett-Johnson
Shillcutt SD. See Coburn KL
Shimon H, Sobolev Y, Davidson M, Haroutunian V, Belmaker RH, Agam G. Inositol levels are dcreased in postmortem brain of schizophrenic patients, 428
Shirakawa O. See Chakos MH
Shively CA. Social subordination stress, behavior, and central monoaminergic function in female cynomolgus monkeys, 882
Shoaf SE. See Hibbeln J
Siegler IC. See Clark LM
Sierra M, Berrios GE. Depersonalization: neurobiological perspectives, 898
Siever LJ. See Yehuda R
Sikich L. See Lieberman JA
Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine, 302
Simpson G. See Meyer JM
Simpson MDC, Slater P, Deakin JFW. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia, 423
Slater P. See Simpson MDC
Smith M. See Thayer JF
Soares JC, Mann JJ. Global structural brain abnormalities in mood disorders: evidence from a meta-analysis versus a traditional review (response), 933-corr (response)
Sobolev Y. See Shimon H
Sofuoglu M. See DeBattista C
Sollers JJ. See Thayer JF
Southwick SM. See Grillon C
Spalletta G. See Rupprecht R
Spellberg BJ. See Wirshing DA
Spencer T. See Biederman J
Srinivasagam NM. See Sweeney JA
Stahl SM. See Seifritz E
Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression, 534
Staner L. See Stefos G
Stanton SP. See Sax KW
Stark KL, Oosting RS, Hen R. Novel strategies to probe the functions of serotonin receptors, 163
State M. See Martin A
Steege D. See Arolt V
Stefos G, Staner L, Kerkhofs M, Hubain P, Mendlewicz J, Linkowski P. Shortened REM latency as a psychobiological marker for psychotic depression? An age-, gender-, and polarity-controlled study, 1314
Stein DJ. See Simeon D
Stein MB
Neurobiological perspectives on social phobia: from affiliation to zoology, 1277
See Nordahl TE
Still S. See Kaufman J
Stolar M. See Rosenheck R
Strakowski SM
See O'Driscoll GA
See Sax KW

Strakowski SM, Sax KW. Progressive behavioral response to repeated d-amphetamine challenge: further evidence for sensitization in humans, 1171
Strober M. See Kaye W
Ströhle A. See Rupprecht R
Subhash MN. See Rao Jagadeesh S
Sullivan PF. See Bulik C
Sun A. See Wirshing DA
Sundström I, Bäckström T.:Patients with premenstrual syndrome have decrease saccadic eye velocity compared to control subjects, 755
Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association, 141
Suzuki Y. See Ohara Koichi
Swanson CL Jr, Gur RC, Bilker W, Petty RG, Gur RE. Premorbid educational attainment in schizophrenia: assocation with symptoms, functioning, and neurobehavioral measures, 739
Sweeney JA, Luna B, Srinivasagam NM, Keshavan MS, Schooler NR, Haas GL, Carl JR. Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields, 698
Swerdlow NR. Startle in Tourette's syndrome, 935-corr
Swingle PG. Neurofeedback treatment of pseudoseizure disorder, 1196

Tamminga CA.
See Chakos MH
Serotonin and schizophrenia, 1079
Tang X. See Li T
Tani K. See Ohara Koichi
Tauscher J, Fischer P, Neumeister A, Rappelsberger P, Kasper S. Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients, 438
Teicher MH. See Yehuda R
Teichert H-M. See Arolt V
Tekeoğlu I. See Ağargün MY
Thayer JF, Smith M, Rossy LA, Sollers JJ, Friedman BH. Heart period variability and depressive symptoms: gender differences, 304
Thomas J. See Rosenheck R
Thompson P. See Piggott MA
Tibbo P, Nopoulos P, Arndt S, Andreasen NC. Corpus callosum shape and size in male patients with schizophrenia, 405
Tilikete S. See Aubin H-J
Tishler TA. See Wirshing DA
Todtenkopf MS. See Benes FM
Touitou Y. See Millet B
Treves TA. See Rabey JM
Troia M. See Berardi D
Trubnick L. See Kaufman J
Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia, 667
Tsai G, Yang P, Chung L-C, Lange N, Coyle JT. D-Serine added to antipsychotics for the treatment of schizophrenia, 1081
Tsuang D. See Peskind ER
Tsuang MT. See Maher BA
Tsukamoto T. See Ohara Koichi
Tucker KA. See Coburn KL
Tupler LA. See Clark LM

Uhde TW. See Nordahl TE
Ulett GA, Han S, Han J.-S. Electroacupuncture: mechanisms and clinical application, 129
Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of clozapine on auditory event-related potentials in schizophrenia, 716
Umhau JC. See Hibbeln J
Unger R. See Mintzer J
Urata K. See Higashima M

Valdes R Jr. See Rose AM
Vallada HP. See Li T
Vallat B. See Aubin H-J
Van Dyck CH. See Malison RT
van Dyck R. See Veltman DJ
van Kammen DP. See Tsai G
van Rijk PP. See Ho Pian KL
van Zijderveld GA. See Veltman DJ
Varma D. See Ryan ND
Vaughan MR. See Hibbeln J
Veltman DJ, van Zijderveld GA, van Dyck R, Bakker A. Predictability, controllability, and fear of symptoms of anxiety in epinephrine-induced panic, 1017
Venetianer P. See Zsurka G
Vernier F. See Aubin H-J
Vincent SL. See Benes FM
Vogel GW. See Rush AJ
Volz H-P, Rzanny R, Rössger G, Hübner G, Kreitschmann-Andermahr I, Kaiser WA, Sauer H. ^{31}Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics—a study including 50 patients and 36 controls, 399
Vrindavanam NS. See Sallee FR

Wadenburg M-LG, Hicks PB, Richter JT, Young KA. Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin$_{2A}$ receptor antagonist MDL 100,907, 508
Weber W. See Seidman LJ
Weinberger D, Charney DS. *Biological Psychiatry—a journal progress report, 377-ed*
Weinberger DR. See Callicott JH
Weiss SRB. See Post RM
Welsh-Bohmer KA. See Clark LM
West SA
See Geracioti TD Jr
See Sax KW
Westenberg HGM. See Ho Pian KL
Whalen PJ, Bush G, McNally RJ, Wilhelm S, McInerney SC, Jenike MA, Rauch SL. The emotional counting Stroop paradigm: a functional magnetic resonance imaging probe of the anterior cingulate affective division, 1219
Wiechers IR. See Friedman L
Wilens TE. See Biederman J
Wilhelm S. See Whalen PJ
Wilkinson CW. See Peskind ER
Williams A. See Gurguis GNM
Winblad B. See Forsell Y
Winokur A. See Rush AJ
Winslow JT. See Insel TR
Wirshing D. See Kern RS
Wirshing DA, Bartzokis G, Pierre JM, Wirshing WC, Sun A, Tishler TA, Marder SR. Tardive dyskinesia and serum iron indices, 493
Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes, 778
Wirshing WC
See Kern RS
See Wirshing DA
Woods DL. See Alain C
Wortman MD. See Geracioti TD Jr

Xie T. See Li T
Xu W. See Rosenheck R

Yamagami S. See Inoue K
Yamaguchi N. See Higashima M
Yang P. See Tsai G
Yang R-K. See Yehuda R
Yehuda R, McFarlane AC, Shalev AY. Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event, 1305
Yehuda R, Siever LJ, Teicher MH, Levengood RA, Gerber DK, Schmeidler J, Yang R-K. Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttramatic stress disorder and major depressive disorder,56
Yonkers KA
See Gurguis GNM
See Rush AJ
Young D. See Griffith JM
Young KA. See Wadenburg M-LG
Yurgelun-Todd DA. See Maher BA

Zametkin A. See Nordahl TE
Zarifian E. See Savoye C
Zerah F. See Aubin H-J
Zhao J. See Li T
Zinger Y. See Lavie P
Zipursky RB. See Roy PD
Zsurka G, Kálmán J, Juhász A, Császár A, Raskó I, Janka Z, Venetianer P. No mitochondrial haplotype was found to increase risk for Alzheimer's disease, 371

Subject Index to Volume 44

Abnormal Involuntary Movement Scale
  tardive dyskinesia and serum iron indices, 493
Abstinence
  recent, sertaline in alcoholics and, 633
Acetylcholine
  nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
  pilocarpine/ipsaspirone sleep probe in major depression and, 21
Achievement
  ADHD in adulthood and, 260
Acknowledgements, 1367
Acoustic startle
  deficient sensorimotor gating after seizures and, 290
  in Vietnam veterans with PTSD, experimental context and explicit threat cue effect on acoustic startle in, 1027
Activation
  cerebral, during smooth pursuit and saccadic eye movements, 685
  hypofrontality and, 787
Acupuncture analgesia
  electroacupuncture and, 129
Adaptation
  genetically-driven variation in serotonin uptake and, 179
Adenosine triphosphate (ATP)
  schizophrenia and MRS, 399
Adolescents
  depressed, parenteral clomipramine challenge in, 562
  fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
  serotonergic therapies in, 336
α_2-Adrenergic receptors
  platelet, premenstrual dysphoric disorder and, 600
β-Adrenergic receptors
  noradrenergic system in CCK-induced panic and, 364
Adrenocorticotropic hormone (ACTH)
  corticotropin-releasing factor in depression and, 15
Adulthood
  ADHD in, 260
Affect
  DRD4 gene and neuroleptic response in schizophrenia, 483
  estrogen-serotonin interactions and, 839
  inositol in schizophrenia and, 428
  serotonin and, 795-ed
Affective disorders
  anterior cingulate affective division and, 1219
  CAG/CTG repeat size in, repeat expansion detection method and, 1160
  genetically-driven variation in serotonin uptake and, 179
  pharmacotherapy of affective disorders in 21st century, 517
  seasonal mood variations and light exposure, 622
  serotonergic mechanisms and, 193
  temporal horn enlargement in schizophrenia and bipolar disorder, 418
Affective psychosis
  first episode, symptom correlates of attentional improvement after hospitalization for, 784
Affective stimuli
  gender differences in electrophysiological responses to facial stimuli, 281
Affiliative behavior
  serotonin and neuropeptides in, 207
  social phobia and, 1277
Age
  ADHD and substance abuse, 269
  ADHD in adulthood and, 260
  amino acid uptake sites in schizophrenia and, 423
  assymetry and schizophrenia onset, 413
  brain abnormalities in elderly depressives and, 34
  corpus callosum in male schizophrenics and, 405
  fourteen and six positive spikes and ADHD, 298
  genetically-driven variation in serotonin uptake and, 179
  mitochondrial haplotypes in Alzheimer's disease and, 371
  MRI correlates of depression in Alzheimer's disease and, 592
  nonpyramidal cells in sector CA2 in schizophrenia and manic depression, 88
  shortened REM latency as psychobiological marker for psychotic depression, 1314
  tardive dyskinesia and serum iron indices, 493
Aggression
  serotonin and neuropeptides in affiliative behaviors, 207
Agitation
  fenfluramine challenge test as marker of serotonin activity in, 918
  SSRI discontinuation syndrome and, 77
Akathisia
  tardive dyskinesia and serum iron indices, 493
Alcohol abuse
  biological markers of heavy drinking and, 638
  concurrent cocaine and alcohol use, 250
Alcoholism
  ADHD and, 269
  essential fatty acids predict CSF serotonin and dopamine metabolites in alcoholism, 235, 243
  genetically-driven variation in serotonin uptake and, 179
  sertaline in depressed recently abstinent alcoholics and, 633
Algometer
  hypnotizability, pain threshold, and dissociative experiences, 69
Allele polymorphism

© 1998 Society of Biological Psychiatry

0006-3223/98/$19.00

mitochondrial haplotypes in Alzheimer's disease and, 371
Allelic associations
in bipolar disorder, *ATP1A3* gene and, 47
dopaminergic receptor genes and manic depression, 644
DRD4 gene and neuroleptic response in schizophrenia, 483
Allopregnanolone
SSRIs and, 865
Alpha subunit gene
Na^+, K^+ adenosine triphosphatase, allelic association between bipolar disorder and, 47
Alpha2 isoform
of Na,K-adenosine triphosphatase, in temporal cortex of bipolar individuals, 892
Alprazolam
and loud tones in panic disorder and PTSD, 64
Alzheimer's disease
fenfluramine challenge test as marker of serotonin activity in, 918
genetically-driven variation in serotonin uptake and, 179
leptin and cortisol in, 374-corr
mitochondrial haplotypes and, 371
MRI correlates of, depression and, 592
psychosis and apolipoprotein E genotypes in elderly population, 139
Amantadine
neuroleptic malignant syndrome and, 378
Aminergic neurons
biological parameters in major depression and, 274
Amino acid uptake sites
schizophrenia and, 423
d-Amphetamine
repeated challenge, personality traits and, 1192
repeated challenge, progressive behavioral response to, 1171
Amphetamines
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Amplitude
deficient sensorimotor gating after seizures and, 290
EEG coherence in neuroleptic-free schizophrenics and, 438
gender differences in electrophysiological responses to facial stimuli, 281
P300 in schizophrenia and, 466
Amygdala
amino acid uptake sites in schizophrenia and, 423
deficient sensorimotor gating after seizures and, 290
extended, in fear vs. anxiety, 1229, 1239
Amygdala-stria terminalis model
anxiety disorders and, 1204
Analgesia
electroacupuncture and, 129
Anger
serotonin transporter and, 550
Anorexia nervosa
serotonin neuronal function and SSRIs in, 825
Anterior cingulate affective division
emotional counting Stroop paradigm and, 1219
Antibiotics
serotonin receptors and, 163
Anticholinergics
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Anticipatory saccades
during smooth pursuit eye movements, familial transmission of schizophrenia and, 690
Anticonvulsants
fourteen and six positive spikes and ADHD, 298
serotonergic mechanisms and, 193
Antidepressants
adolescent and childhood depression, 336
antidepressant treatments in 21st century, 526
biological parameters in major depression and, 274
bupropion slow-release response in depression and, 629
cocaine withdrawal and serotonin function, 578
d-fenfluramine in major depression and, 555
genetically-driven variation in serotonin uptake and, 179
5-HT mechanisms in depression and OCD, 313
intracellular Ca^{++} in frontal cortex and, 617
novel therapeutic approaches beyond serotonin receptor, 324
risks and benefits of combining SSRIs with other serotonergic drugs, 341
sertaline in depressed recently abstinent alcoholics and, 633
sleep and, 3
sleep and, 1-ed
SSRI discontinuation syndrome and, 77
SSRI elimination half-lives and, 75-ed
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Antidysphoric profiles
SSRIs and, 865
Antipsychotics
novel, new onset diabetes and, 778
D-serine with, scizophrenia and, 1081
serotonergic basis of effects, schizophrenia and, 1099
Anti-saccade distractibility
antisaccade and no-saccade, chlorpromazine and lorazepam effects on, 709
Antisense strategy
affective disorders and, 517
Antiserum
electroacupuncture and, 129
Anxiety
alprazolam in panic disorder and PTSD, 64
brain neurocircuitry and, 1201
dexamethasone window in Chinese depressives and, 648
electroacupuncture and, 129
emotion and, 1248
epinephrine-induced panic and, 1017
extended amygdala and, 1229, 1239
fourteen and six positive spikes and ADHD, 298
inhibition of, by antisense to cholecystokinin precursor protein, 915
motivation and, 1248
neural circuits and, 1229, 1239, 1248

pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
seasonal mood variations and light exposure, 622
serotonin and, 151
SSRI discontinuation syndrome and, 77
transcranial magnetic stimulation in PTSD and, 52
Anxiety disorders
amygdala-stria terminalis model and, 1204
fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
genetically-driven variation in serotonin uptake and, 179
neurobiology and, 1264, 1277, 1286, 1295, 1305
SSRIs and, 812, 865
Apolipoprotein A1
biological markers of heavy drinking and, 638
Apolipoprotein E
genotypes, and psychosis in elderly population, 139
Apolipoprotein E4
mitochondrial haplotypes in Alzheimer's disease and, 371
Arachidonic acid
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
Arithmetic
written, ADHD in adulthood and, 260
Aspartate
amino acid uptake sites in schizophrenia and, 423
Aspartate aminotransferase
biological markers of heavy drinking and, 638
Association studies
bipolar disorder and, 47
dopaminergic receptor genes and manic depression, 644
MN blood groups in major depression and, 361
Asymmetry
P300 in schizophrenia and, 466
regional cerebral metabolic, panic disorder and, 998
schizophrenia onset and, 413
ATP1A3 gene
allelic association between bipolar disorder and, 47
Atrophy
neuronal, novel therapeutic approaches beyond serotonin receptor, 324
Attachment
serotonin and neuropeptides in affiliative behaviors, 207
Attention
quantitative measurement of eye movements in schizophrenia and, 448
symptom correlates of attentional improvement after hospitalization for first episode affective psychosis, 784
visual, schizophrenia and, 1151
Attention-deficit hyperactivity disorder (ADHD)
adulthood and, 260
fourteen and six positive spikes and, 298
neurobiology and, 951
stress response and, 72
substance abuse and, 269
Atypical antipsychotics
raclopride and MDL 100,907, 508
Atypical depression
bupropion slow-release response in, 629
Auditory distractors
quantitative measurement of eye movements in schizophrenia and, 448
Auditory event-related potentials
clozapine in schizophrenia and, 716
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
Auditory oddball paradigm
high-density recording and topographic analysis in schizophrenia, 982
schizophrenia and, 115
Auditory startle
alprazolam in panic disorder and PTSD, 64
Auditory stimuli
processing of during visual attention in schizophrenics, 1151
Augmentation
antidepressant, risks and benefits of combining SSRIs with other serotonergic drugs, 341
Autism
genetically-driven variation in serotonin uptake and, 179
Autonomic nervous system
heart period variability and depression, 304
Autoreceptors
cocaine withdrawal and serotonin function, 578
5-HT mechanisms in depression and OCD, 313
Avolition
DRD4 gene and neuroleptic response in schizophrenia, 483
Awaking thresholds
elevated during sleep, in chronic war-related PTSD, 1060
Axillary temperature
plasma melatonin and cortisol in obsessive-compulsive disroder and, 874
Axons
serotonergic neurons and their projections, 145

Basolateral amygdala
deficient sensorimotor gating after seizures and, 290
Beck Depression Inventory
bupropion slow-release response in depression and, 629
sertaline in depressed recently abstinent alcoholics and, 633
Beck Melancholia Scale
d-fenfluramine in major depression and, 555
Behavior
affiliative, serotonin and neuropeptides in, 207
d-amphetamine challange and, 1171, 1192
concurrent cocaine and alcohol use, 250
eating, hypothalamic serotonin and, 851
female cynomolgus monkeys and, 882
raclopride and MDL 100,907, 508
spectrum of influenced by serotonin, 151
Behavioral sensitization
β-noradrenergic system in CCK-induced panic and, 364
serotonergic mechanisms and, 193
Benzodiazepines
serum iron in catatonia and neuroleptic malignant syndrome, 499

Beta blockers
5-HT mechanisms in depression and OCD, 313
β-noradrenergic system in CCK-induced panic and, 364
Binge-eating
genetic epidemiologic studies and, 1208
heritability and, 1210
Biological markers
psychotic depression and, 1314
Biological phenotypes
genetics of schizophrenia and, 939
Biological Psychiatry journal progress report, 377-ed
Biopterins
biological parameters in major depression and, 274
Bipolar disorder
association study in, 47
bupropion slow-release response in, 629
CAG/CTG repeat size in, repeat expansion detection method and, 1160
dopaminergic receptor genes in, 644
inositol in schizophrenia and, 428
MN blood groups in, 361
temporal cortex in, alpha2 isoform of Na,K-adenosine triphosphatase and, 892
temporal horn enlargement in, 418
Blunt affect
DRD4 gene and neuroleptic response in schizophrenia, 483
Body weight
hypothalamic serotonin and, 851
Bonferroni's correction
multiple correlations and, 775
Brain-derived neurotrophic factor (BDNF)
novel therapeutic approaches beyond serotonin receptor, 324
Brain neurocircuitry
in anxiety and fear, 1201
panic disorder and, 1264
Brief Psychiatric Rating Scale
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Brief Symptom Inventory
d-fenfluramine in major depression and, 555
Bright light
seasonal mood variations and light exposure, 622
Bromocriptine
neuroleptic malignant syndrome and, 378
Bulimia nervosa
broadly-defined, heritability and, 1210
genetic epidemiologic studies and, 1208
serotonin neuronal function and SSRIs in, 825
Bupropion
slow-release response in depression and, 629

Ca^{++}
intracellular, antidepressant effect on in frontal cortex, 617
Caffeine
biological markers of heavy drinking and, 638
CAG/CTG repeat size
in schizophrenia and bipolar disorder, repeat expansion detection method and, 1160
Carbamazepine
with long-term neuroleptic treatment, neuroleptic malignant syndrome and, 930
Carbon monoxide
biological markers of heavy drinking and, 638
[123I]-Carbomethoxy-3B-(4-iodephenyl)tropane
serotonin transporter in major depression and, 1090
Cardiovascular sensitivity
β-noradrenergic system in CCK-induced panic and, 364
Cardiovascular system
heart period variability and depression, 304
Case-control studies
clinical and pharmacological risk factors for neuroleptic malignant syndrome, 748
schizophrenia and homocysteine metabolism, 141
Catatonia
serum iron in, 499
Catecholamines
bupropion slow-release response in depression and, 629
d-fenfluramine in major depression and, 555
plasma norepinephrine and 3-MHPG levels in PTSD, 56
Caudate nucleus
mCPP effects on cerebral blood flow in OCD and, 367
Cell proliferation
genetically-driven variation in serotonin uptake and, 179
Central monoaminergic function
female cynomolgus monkeys and, 882
Central nervous system (CNS)
affective disorders and, 517
dopamine and serotonin metabolites in human CSF, 228
genetically-driven variation in serotonin uptake and, 179
Cerebellum
inositol in schizophrenia and, 428
mCPP effects on cerebral blood flow in OCD and, 367
Cerebral blood flow
in obsessive-compulsive disorder, mCPP and, 367
Cerebral cortex
amino acid uptake sites in schizophrenia and, 423
EEG coherence in neuroleptic-free schizophrenics and, 438
Cerebrospinal fluid (CSF)
dopamine and serotonin metabolites in, 228
electroacupuncture and, 129
inositol monophosphatase, in depression and neuroleptic-treated schizophrenia, 433
monoamines, Prader-Willi syndrome and, 1321
oxytocin, Prader-Willi syndrome and, 1349
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Cerebrovascular disease
MRI correlates of depression in Alzheimer's disease and, 592
Children
ADHD and substance abuse, 269
depressed abused, serotonergic functioning in, 973
fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
peripheral serotonin measures and suicidal behavior, 568
serotonergic therapies in, 336

Chinese subjects
CAG/CTG repeat size in schizophrenia and bipolar disorder, repeat expansion detection method and, 1160
dexamethasone window in, 648
Chinese medicine
electroacupuncture and, 129
m-Chlorophenylpiperazine
metabolism, CYP2D6 and, 1185
Chlorpromazine
antisaccade and no-saccade distractibility, 709
schizophrenia and MRS, 399
Cholecystokinin precursor protein
antisense to, anxiety inhibition and, 915
Cholecystokinin tetrapeptide (CCK4)
panic induced by, β-noradrenergic system and, 364
Cholesterol
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
Cholinergic neurons
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
Cholinergic REM induction
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Choreoathetoid movements
tardive dyskinesia and serum iron indices, 493
Chromosomal location
human gamma-aminobutyric acid B receptor gene and, 659
Chromosome 4q28-q31.1
MN blood groups in major depression and, 361
Chronobiological analyses
plasma norepinephrine and 3-MHPG levels in PTSD, 56
Circadian rhythms
plasma norepinephrine and 3-MHPG levels in PTSD, 56
Clinical Global Impression Scale
d-fenfluramine in major depression and, 555
sertaline in depressed recently abstinent alcoholics and, 633
transcranial magnetic stimulation in PTSD and, 52
Clinical validity
competing models of positive symptoms in schizophrenia and, 107
Clomipramine
intravenous challenge, obsessive-compulsive disorder and, 220
Cloning
human gamma-aminobutyric acid B receptor gene and, 657-ed, 659
Clozapine
auditory event-related potentials in schizophrenia and, 716
plasma concentrations, patient variables and, 733
schizophrenia and, 475
Cocaethylene
concurrent cocaine and alcohol use, 250
Cocaine
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
withdrawal, serotonin and, 578
Coffee
biological markers of heavy drinking and, 638
Cognitive function
brain abnormalities in elderly depressives and, 34
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Coherence analysis
EEG coherence in neuroleptic-free schizophrenics and, 438
Combat veterans
plasma norepinephrine and 3-MHPG levels in PTSD, 56
with PTSD, elevated awaking thresholds during sleep and, 1060
with PTSD, experimental context and explicit threat cues effects on acoustic startle in, 1027
Comorbidity
psychiatric, ADHD in adulthood and, 260
psychoactive substance use disorder and ADHD, 269
Compensations
developmental, serotonin receptors and, 163
Complementary DNA (cDNA)
cloning, human gamma-aminobutyric acid B receptor gene and, 659
Computed tomography
serotonin synapse in depression and, 534
slow-wave sleep and ventricular size in schizophrenia and major depression, 121
Conditioned avoidance response behavior
raclopride and MDL 100,907, 508
Confirmatory factor analysis
competing models of positive symptoms in schizophrenia and, 107
Constant velocity
quantitative measurement of eye movements in schizophrenia and, 448
Contextual sensitization
alprazolam in panic disorder and PTSD, 64
Continuous covariability
of dopamine and serotonin metabolites in human CSF, 228
Continuum of liability
slow-wave sleep and ventricular size in schizophrenia and major depression, 121
Controllability
epinephrine-induced panic and, 1017
Corpus callosum
male patients with schizophrenia and, 405
Corticolimbic regions
nonpyramidal cells in sector CA2 in schizophrenia and manic depression, 88
Corticotrophin-releasing factor (CRF)
affective disorders and, 517
Corticotropic hormone
corticotropin-releasing factor in depression and, 15
Corticotropin-releasing factor (CRF)
plasma levels, depressive disorders and, 15
Cortisol
ADHD and stress response, 72
Alzheimer's disease and-corr, 374
corticotropin-releasing factor in depression and, 15

dexamethasone window in Chinese depressives and, 648
d-fenfluramine in major depression and, 555
plasma, obsessive-compulsive disorder and, 874
Cos-7 cells
serotonin receptors and, 163
Cotinine
biological markers of heavy drinking and, 638
Coupling
G_i protein, platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
CREB protein
novel therapeutic approaches beyond serotonin receptor, 324
Cross-perfusion experiments
electroacupuncture and, 129
Cross-sensitization
serotonergic mechanisms and, 193
Cyclic adenosine monophosphate (cAP)
novel therapeutic approaches beyond serotonin receptor, 324
Cynomolgus monkeys
social subordination stress, behavior, and central monoaminergic function in female, 882
CYP2D6
m-chlorophenylpiperazine metabolism and, 1185

D2 receptor
dopamine, raclopride and MDL 100,907, 508
Daily living disability
psychosis and apolipoprotein E genotypes in elderly population, 139
Dantrolene
neuroleptic malignant syndrome and, 378
Degeneration
genetically-driven variation in serotonin uptake and, 179
Delta power suppression
EEG, pilocarpine/ipsaspirone sleep probe in major depression and, 21
Delusions
competing models of positive symptoms in schizophrenia and, 107
schizophrenia and, 107
Dementia
fenfluramine challenge test as marker of serotonin activity in, 918
genetically-driven variation in serotonin uptake and, 179
mitochondrial haplotypes in Alzheimer's disease and, 371
MRI correlates of depression in Alzheimer's disease and, 592
psychosis and apolipoprotein E genotypes in elderly population, 139
Demographic variables
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Dependence
ADHD and substance abuse, 269
Depersonalization disorder
clomipramine and, 302
neurobiological perspective and, 898
Depression
association study in, 47
biological parameters in, 274
brain abnormalities in, 34
bupropion slow-release response in, 629
CA2 in, 88
clomipramine in, 562
cocaine withdrawal and serotonin function, 578
corticotropin-releasing factor plasma levels in, 15
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
dexamethasone window in, 648
dopaminergic receptor genes in, 644
electroacupuncture in, 129
essential fatty acids predict CSF serotonin and dopamine metabolites in alcoholism, 235, 243
d-fenfluramine in, 555
gender differences in heart period variability, 304
generalizable model of symptoms in, 959
imaging serotonin synapse in, 534
intracellular Ca^{++} in frontal cortex in, 617
in vivo neurotransmitter imaging studies in, 1077
lithium in recurrent, brief, 927
long-term maintenance treatment in, 348
metyrapone and neuroactive steroid concentrations, 912
3-MHPG plasma levels in, 56
MN blood groups in, 361
MRI correlates of Alzheimer's disease in, 592
nefadozone and fluoxetine effects on sleep and, 3
norepinephrine plasma levels in, 56
parenteral clomipramine challenge in, 562
pilocarpine/ipsaspirone sleep probe in, 21
platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
platelet protein kinase C in, 909
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
protein kinase C in, 909
recurrent brief, lithium in, 927
REM latency as psychobiological marker in, 1314
seasonal mood variations and light exposure in, 622
serotonergic function in, 151, 313, 555, 973
serotonergic therapies in adolescent and childhood depression, 336
serotonin transporter in, 550, 1090
sertaline in depressed recently abstinent alcoholics and, 633
slow-wave sleep and ventricular size in, 121
SSRI discontinuation syndrome in, 77
SSRI elimination half-lives in, 75-ed
Desensitization
nicotinic receptor, schizophrenia and, 98
Desipramine
clomipramine and depersonalization disorder, 302
Development
ADHD and stress response, 72
ADHD and substance abuse, 269
genetically-driven variation in serotonin uptake and, 179

predicting, posttraumatic stress disorder and, 1305
serotonergic neurons and their projections, 145
serotonin receptors and, 163
Dexamethasone suppression test (DST)
window, Chinese depressives and, 648
Dexterity
manual, risperidone vs haloperidol in treatment-resistant schizophrenia, 726
Diabetes
new onset, novel antipsychotics and, 778
Differentiation
of embryonic brain, serotonergic neurons and their projections, 145
Discriminant analysis
quantitative measurement of eye movements in schizophrenia and, 448
Discrimination task
facial, gender differences in electrophysiological responses to facial stimuli, 281
Dissociative experiences
clomipramine and depersonalization disorder, 302
and hypnotizability and pain threshold, 69
Dissociative Experiences Scale
hypnotizability, pain threshold, and dissociative experiences, 69
Distractibility
antisaccade and no-saccade, chlorpromazine and lorazepam effects on, 709
Distractors
quantitative measurement of eye movements in schizophrenia and, 448
Dizziness
SSRI discontinuation syndrome and, 77
DNA mutation
mitochondrial haplotypes in Alzheimer's disease and, 371
Docosahexaenoic acid
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
DOI
cocaine withdrawal and serotonin function, 578
Dopamine
CSF metabolites, predicted by essential fatty acids in alcoholism, 235, 243
D1 receptor, repetitive jaw movements and, 1178
D_1, D_2, D_3 receptor genes, manic depression and, 644
D2 receptor, raclopride and MDL 100,907, 508
DRD4 gene, neuroleptic response in schizophrenia and, 483
metabolites, human CSF and, 228
nigrostriatial dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity, 765
P50 amplitude and, 935-corr
striatal and prefrontal metabolism, space restriction-induced rebound hyperphagia and, 1329
uptake, by platelet storage granules in first degree relatives of Tourette's syndrome patients, 1166
Dorsolateral prefrontal region
schizophrenia and MRS, 399
Dosing nomogram
patient variables and plasma clozapine concentrations, 733
DRD4 gene
dopamine, neuroleptic response in schizophrenia and, 483
Drinking
heavy, biological markers of, 638
Drug abuse
ADHD and, 269
cocaine withdrawal and serotonin function, 578
concurrent cocaine and alcohol use, 250
electroacupuncture and, 129
genetically-driven variation in serotonin uptake and, 179
Drug interactions
risks and benefits of combining SSRIs with other serotonergic drugs, 341
Drug-free period
inpatient, pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Drug-naive patients
slow-wave sleep and ventricular size in schizophrenia and major depression, 121
Duration of illness
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Dynorphins
electroacupuncture and, 129
Dysphoria
SSRIs and, 865
Dysthymia
corticotropin-releasing factor plasma levels in, 15

Early-onset depression
brain abnormalities in, 34
Eating behavior
hypothalamic serotonin and, 851
Eating disorders
genetic epidemiologic studies and, 1208
Education
ADHD in adulthood and, 260
premorbid attainment, schizophrenia and, 739
psychosis and apolipoprotein E genotypes in elderly population, 139
Elderly
brain abnormalities in depression and, 34
MRI correlates of depression in Alzheimer's disease and, 592
psychosis and apolipoprotein E genotypes in, 139
Electroacupuncture
mechanisms and clinical application, 129
Electroconvulsive therapy (ECT)
biological parameters in major depression and, 274
plasma vasopressin and oxytocin affected by, 610
serum iron in catatonia and neuroleptic malignant syndrome, 499
Electroencephalogram (EEG)
brain abnormalities in elderly depressives and, 34
coherence, schizophrenia and, 438
fourteen and six positive spikes and ADHD, 298
nefadozone and fluoxetine effects on sleep and, 1-ed, 3

P300 in schizophrenia and, 466
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Electrophysiology
prefrontal serotonin systems and, 1118
Elimination half-lives
SSRIs and, 75-ed
Embryonic brain
serotonergic neurons and their projections, 145
Emotion
anxiety and, 1248
emotional impact of stimuli, event-related potentials to in PTSD, 1045
gender differences in electrophysiological responses to facial stimuli, 281
Emotional abuse
serotonergic functioning in depressed abused children, 973
Emotional counting Stroop paradigm
MRI of anterior cingulate affective division and, 1219
Endorphins
electroacupuncture and, 129
Enhanced behavioral response
to repeated d-amphetamine challenge, personality traits and, 1192
Enkephalins
electroacupuncture and, 129
Epidemiologic studies
genetic, binge-eating and bulimia, 1208
Epilepsy
deficient sensorimotor gating after seizures and, 290
fourteen and six positive spikes and ADHD, 298
Essential fatty acids (EFAs)
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
Estrogen
mood disturbance and, 798
serotonin interactions with, affective regulation and, 839
Ethnicity
CAG/CTG repeat size in schizophrenia and bipolar disorder, repeat expansion detection method and, 1160
dexamethasone window in Chinese depressives and, 648
peripheral serotonin measures and suicidal behavior, 568
Euphoria
concurrent cocaine and alcohol use, 250
Event-related potentials
brain abnormalities in elderly depressives and, 34
clozapine in schizophrenia and, 716
gender differences in electrophysiological responses to facial stimuli, 281
high-density recording and topographic analysis in schizophrenia, 982
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
schizophrenia and, 115
to stimuli with emotional impact, PTSD and, 1045
Excitability
schizophrenia and, 115
Excited catatonia
serum iron in catatonia and neuroleptic malignant syndrome, 499
Executive function tests
ADHD in adulthood and, 260
Exons
DRD4 gene and neuroleptic response in schizophrenia, 483
Experimental context
effects of on acoustic startle in Vietnam veterans with PTSD, 1027
Explicit threat cues
effects of on acoustic startle in Vietnam veterans with PTSD, 1027
Exploration
serotonin and neuropeptides in affiliative behaviors, 207
Expressions
facial, gender differences in electrophysiological responses to facial stimuli, 281
Extrapyramidal symptoms
raclopride and MDL 100,907, 508
tardive dyskinesia and serum iron indices, 493
Eyeblink electromyogram
alprazolam in panic disorder and PTSD, 64
Eye movements
mooth pursuit, anticipatory saccades during in schizophrenia, 690
quantitative measurements of in schizophrenia and, 448
schizophrenia and, 698
smooth pursuit and saccadic, cerebral activation during, 685

Facial discrimination task
gender differences in electrophysiological responses to facial stimuli, 281
Facial stimuli
gender differences in electrophysiological responses to, 281
Factor analysis
schizophrenia and, 115
Factor structure
competing models of positive symptoms in schizophrenia and, 107
Family studies
anticipatory saccades during smooth pursuit eye movements and familial transmission of schizophrenia, 690
fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
hippocampal N-acetyl aspartate in unaffected siblings of schizophrenics, 941
Fear
brain neurocircuitry and, 1201
epinephrine-induced panic and, 1017
extended amygdala and, 1229, 1239
neural circuits and, 1229, 1239, 1248
Fear-potentiated startle
in adolescent offspring of patents with anxiety disorders, 990
Feeding
serotonin and, 151, 795-ed

d-Fenfluramine
challenge test, as serotonin activity marker in Alzheimer's dementia and agitation, 918
cocaine withdrawal and serotonin function, 578
major depression and, 555
Ferritin
tardive dyskinesia and serum iron indices, 493
Filtering deficits
schizophrenia and, 98
First degree relatives
of Tourette's syndrome patients, dopamine uptake by platelet storage granules in, 1166
First episode of illness
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Fluorescence histochemistry
affective disorders and, 517
Fluoxetine
elimination half-lives and, 75-ed
intracellular Ca^{++} in frontal cortex and, 617
sleep and, 1, 3-ed
SSRI discontinuation syndrome and, 77
Fluphenazine decanoate
tardive dyskinesia and serum iron indices, 493
Folate
deficiency, biological markers of heavy drinking and, 638
schizophrenia and homocysteine metabolism, 141
Fourteen and six positive spikes
ADHD and, 298
Frequency domain measures
heart period variability and depression, 304
Frontal cortex
antidepressant effect on intracellular Ca^{++}, 617
inositol in schizophrenia and, 428
mCPP effects on cerebral blood flow in OCD and, 367
Frontal eye fields
schizophrenia and, 698
Frontal lobes
ADHD in adulthood and, 260
amino acid uptake sites in schizophrenia and, 423
assymetry and schizophrenia onset, 413
schizophrenia and, 382
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Functional brain imaging
schizophrenia and MRS, 382, 399
Functional polymorphism
serotonin transporter in mood disorders and, 550

GABAergic neurons
amino acid uptake sites in schizophrenia and, 423
β-Galactosidase
serotonin receptors and, 163
Gamma-aminobutyric acid
amino acid uptake sites in schizophrenia and, 423
schizophrenia and, 382
Gamma-aminobutyric acid B receptor gene
human, cloning and, 657-ed, 659
Gamma-glutamyl transferase
biological markers of heavy drinking and, 638
Gas chromatography
inositol in schizophrenia and, 428
Gastrointestinal disorders
electroacupuncture and, 129
Gating
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
sensorimotor, after seizures, 290
Gender
ADHD and substance abuse, 269
ADHD in adulthood and, 260
corpus callosum in male patients with schizophrenia, 405
DRD4 gene and neuroleptic response in schizophrenia, 483
fourteen and six positive spikes and ADHD, 298
gender differences in electrophysiological responses to facial stimuli, 281
heart period variability and depressive symptoms, 304
mitochondrial haplotypes in Alzheimer's disease and, 371
parenteral clomipramine challnge in depressed adolescents, 562
plasma norepinephrine and 3-MHPG levels in PTSD, 56
premenstrual syndrome and saccadic eye velocity, 755
psychosis and apolipoprotein E genotypes in elderly population, 139
REM latency as psychobiological marker for psychotic depression, 1314
social subordination stress, behavior, and central monoaminergic function in female cynomolgus monkeys, 882
SPECT study of hypofrontality in neuroleptic-naive and neuroleptic-free female schizophrenics, 787
tardive dyskinesia and serum iron indices, 493
Generalizable model of symptoms
major depressive disorder and, 959
Generalized anxiety disorder (GAD)
neurobiological and pharmacotherapeutic perspectives, 1286
Generalized hyperresponsiveness
PTSD and, 1037
Gene targeting
serotonin receptors and, 163
Genetics
binge-eating and bulimia, 1208
biological phenotypes and genetics of schizophrenia, 939
bipolar disorder and, 47
CAG/CTG repeat size in schizophrenia and bipolar disorder, 1160
cloning human gamma-aminobutyric acid B receptor gene, 657-ed, 659
CYP2D6 and m-chlorophenylpiperazine metabolism, 1185
dopaminergic receptor genes and manic depression, 644
DRD4 gene and neuroleptic response in schizophrenia, 483
genetically-driven variation in serotonin uptake, 179
heritability of binge-eating and broadly-defined bulimia nervosa, 1210
mitochondrial haplotypes in Alzheimer's disease and, 371
molecular biology of serotonin receptors, 1128

monoamine oxidase-A gene and major psychosis in Japanese subjects, 922
psychosis and apolipoprotein E genotypes in elderly population, 139
schizophrenia and homocysteine metabolism, 141
serotonin receptors and, 163
serotonin transporter in mood disorders and, 550
Gene transfer
genetically-driven variation in serotonin uptake and, 179
Genomic organization
human gamma-aminobutyric acid B receptor gene and, 659
Genotypic association
MN blood groups in major depression and, 361
Gestation
early, schizophrenia and homocysteine metabolism, 141
Gilles de la Tourette syndrome
temporal dynamics of tics and, 1337
G_i protein coupling
platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
Glia
amino acid uptake sites in schizophrenia and, 423
Global impairments
brain abnormalities in elderly depressives and, 34
Global negative rating
DRD4 gene and neuroleptic response in schizophrenia, 483
Global structural brain abnormalities
mood disorders and, 932-corr 933-corr (response)
Glutamate
amino acid uptake sites in schizophrenia and, 423
schizophrenia and, 382
Glutamatergic neurotransmission
schizophrenia and, 667
G protein-coupled receptors
antidepressant treatments in 21st century, 526
Gray matter
assymetry and schizophrenia onset, 413
MRI correlates of depression in Alzheimer's disease and, 592

Habituation
alprazolam in panic disorder and PTSD, 64
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
Hallucinations
schizophrenia and, 115
Haloperidol
P300 in schizophrenia and, 466
schizophrenia and, 475
Haloperidone
treatment-resistant schizophrenia and, 726
Hamilton Anxiety Rating Scale
alprazolam in panic disorder and PTSD, 64
Hamilton Depression Rating Scale
bupropion slow-release response in depression and, 629
sertaline in depressed recently abstinent alcoholics and, 633
SSRI discontinuation syndrome and, 77
Haplotypes
mitochondrial, Alzheimer's disease and, 371
Happy expressions
facial, gender differences in electrophysiological responses to facial stimuli, 281
Hardy-Weinberg disequilibrium
MN blood groups in major depression and, 361
Heart period variability
gender differences in, depression and, 304
Heart rate
alprazolam in panic disorder and PTSD, 64
concurrent cocaine and alcohol use, 250
variability in PTSD, trauma-related reminder in, 1054
Heritability
binge-eating and broadly-defined bulimia nervosa, 1210
High-density recording
auditory oddball event-related potential in schizophrenia and, 982
High-performance liquid chromatography (HPLC)
dopamine and serotonin metabolites in human CSF, 228
Hindbrain
serotonergic neurons and their projections, 145
Hippocampus
amino acid uptake sites in schizophrenia and, 423
N-acetyl aspartate in unaffected siblings of schizophrenics, 941
nonpyramidal cells in sector CA2 in schizophrenia and manic depression, 88
novel therapeutic approaches beyond serotonin receptor, 324
Homocysteine
metabolism impairment, schizophrenia and, 141
Homovanillic acid (HVA)
bupropion slow-release response in depression and, 629
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
dopamine and serotonin metabolites in human CSF, 228
plasma, schizophrenia and, 488
Hostility
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
schizophrenia and, 115
serotonin transporter aad, 550
Human immunodeficiency virus (HIV)
differential sensitivities to risperidone and olanzapine in, 791
Humoral factors
electroacupuncture and, 129
Hungarian population
mitochondrial haplotypes in Alzheimer's disease and, 371
5-Hydroxyindoleacetic acid (5-HIAA)
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
dopamine and serotonin metabolites in human CSF, 228
5-Hydroxytryptamine (5-HT)
See Serotonin
Hyperactivity
ADHD and stress response, 72

Hyperinnervation
glutamate, amino acid uptake sites in schizophrenia and, 423
Hyperintensity
MRI correlates of depression in Alzheimer's disease and, 592
Hypernatremia
panic disorder and, 1007
Hyperphagia
rebound, space restriction-induced, 1329
Hyperresponsiveness
generalized, PTSD and, 1037
Hypertonic sodium chloride
panic disorder and, 1007
Hypnotic Induction Profile
hypnotizability, pain threshold, and dissociative experiences, 69
Hypnotizability
and pain threshold and dissociative experiences, 69
Hypofrontality
EEG coherence in neuroleptic-free schizophrenics and, 438
resting and activation issue of, 787
Hyporesponsivity
skin conductance, schizophrenia and, 459
Hypothalamic-pituitary-adrenal (HPA) axis
ADHD and stress response, 72
dexamethasone window in Chinese depressives and, 648
Hypothalamus
serotonin in eating behabior, meal size, and body weight, 851
Hypoxemia
biological markers of heavy drinking and, 638

Illness progression
serotonergic mechanisms in, 193
Imipramine
intracellular Ca^{++} in frontal cortex and, 617
Impact of Event Scale
transcranial magnetic stimulation in PTSD and, 52
IMPase
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
Impulsivity
ADHD and stress response, 72
essential fatty acids predict CSF serotonin and dopamine metabolites in alcoholism, 235, 243
Inattentiveness
ADHD and stress response, 72
Inducible knockouts
serotonin receptors and, 163
Inhibition
anxiety and, 915
prepulse, deficient sensorimotor gating after seizures and, 290
In Memoriam (Markku Linnoila), 307
Inositol
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
Inositol monophosphatase
CSF, in depression and neuroleptic-treated schizophrenia, 433
In situ hybridization
affective disorders and, 517
Insomnia
SSRI discontinuation syndrome and, 77
Institutionalization
psychosis and apolipoprotein E genotypes in elderly population, 139
Intermediate neurobiological phenotype
hippocampal N-acetyl aspartate in unaffected siblings of schizophrenics and, 941
Intracellular messengers
antidepressant treatments in 21st century, 526
Intravenous challenge
clomipramine, obsessive-compulsive disorder and, 220
In vivo neurotransmitter imaging studies
major depression aand, 1077
Involuntary movements
tardive dyskinesia and serum iron indices, 493
Iodine-125 radioimmunoassay
corticotropin-releasing factor in depression and, 15
Iron
serum, in catatonia and neuroleptic malignant syndrome, 499
serum, tardive dyskinesia and, 493
Isoform
alpha2 of Na,K-adenosine triphosphatase, in temporal cortex of bipolar individuals, 892
Isoproterenol
β-noradrenergic system in CCK-induced panic and, 364

Japanese sybjects
monoamine oxidase-A gene and major psychosis, 922

Kainate
deficient sensorimotor gating after seizures and, 290
Kainic acid
intracerebroventricular, schizophrenia and, 1143
Kinases
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Kindling
deficient sensorimotor gating after seizures and, 290
serotonergic mechanisms and, 193
Knockouts
serotonin receptors and, 163

Lactate
panic disorder and, 1007
Landmark-based analysis
corpus callosum in male schizophrenics, 405
Latency
gender differences in electrophysiological responses to facial stimuli, 281
P300 in schizophrenia and, 466
REM, pilocarpine/ipsaspirone sleep probe in major depression and, 21

REM, as psychobiological marker for psychotic depression, 1314
REM, slow-wave sleep and ventricular size in schizophrenia and major depression, 121
sleep, nefadozone and fluoxetine effects on, 1-ed, 3
Late-onset depression
brain abnormalities in, 34
Lateralization
assymetry and schizophrenia onset, 413
brain abnormalities in elderly depressives and, 34
P300 in schizophrenia and, 466
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Learning
ADHD in adulthood and, 260
motor, risperidone vs haloperidol in treatment-resistant schizophrenia, 726
premorbid attainment, schizophrenia and, 739
"Leaving one out" method
quantitative measurement of eye movements in schizophrenia and, 448
Leptin
Alzheimer's disease and, 374-corr
Lewy bodies
dementia with, nigrostriatial dopaminergic activities and, 765
Light exposure
seasonal mood variations and, 622
Limbic system
deficient sensorimotor gating after seizures and, 290
Linnoila, Markku (In Memoriam), 307
Lithium
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
inositol in schizophrenia and, 428
MN blood groups in major depression and, 361
recurrent brief depression and, 927
serum iron in catatonia and neuroleptic malignant syndrome, 499
Locomoter activity
serotonin and neuropeptides in affiliative behaviors, 207
Longitudinal studies
ADHD and stress response, 72
Lorazepam
antisaccade and no-saccade distractibility, 709
Loud tones
alprazolam in panic disorder and PTSD, 64
Luteal phase
menstrual cycle, platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600

Magnetic resonance imaging (MRI)
anterior cingulate affective division and emotional counting Stroop paradigm, 1219
assymetry and schizophrenia onset, 413
brain abnormalities in elderly depressives and, 34
corpus callosum in male schizophrenics, 405
correlates of depression in Alzheimer's disease and, 592
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Magnetic resonance spectroscopy (MRS)
schizophrenia and, 382, 399
Maintenance treatment
recurrent unipolar major depression and, 348
Major depressive disorder
biological parameters in, 274
clomipramine in, 562
cocaine withdrawal and serotonin function, 578
corticotropin-releasing factor plasma levels in, 15
d-fenfluramine in, 555
generalizable model of symptoms in, 959
in vivo neurotransmitter imaging studies in, 1077
MRI correlates of Alzheimer's disease in, 592
nefadozone and fluoxetine effects on sleep and, 3
parenteral clomipramine challenge in, 562
pilocarpine/ipsaspirone sleep probe in, 21
plasma norepinephrine and 3-MHPG levels in, 56
serotonergic function in, 555
serotonin synapse in depression and, 534
serotonin transporter in, 1090
slow-wave sleep and ventricular size in, 121
Malignant catatonia
serum iron in catatonia and neuroleptic malignant syndrome, 499
Maltreatment
serotonergic functioning in depressed abused children, 973
Manic depressive disorder
association study in, 47
CA2 in, 88
dopaminergic receptor genes in, 644
Mannitol
inositol in schizophrenia and, 428
Manual dexterity
risperidone vs haloperidol in treatment-resistant schizophrenia, 726
MDL 100,907
raclopride and, 508
Meal size
hypothalamic serotonin and, 851
Mean corpuscular volume
biological markers of heavy drinking and, 638
"Meaningfulness"
of stimuli, skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Melatonin
m-chlorophenylpiperazine, CYP2D6 and, 1185
plasma, obsessive-compulsive disorder and, 874
Memory
ADHD in adulthood and, 260
Menstrual cycle
platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
Meta-analysis
of global structural brain abnormalities and mod disorders, 932-corr, 933-corr (response)

Metabolic asymmetries
regional cerebral, panic disorder and, 998
Metabolism
homocysteine, schizophrenia and, 141
prefrontal and striatal dopamine, during enhanced rebound hyperphagia induced by space restriction, 1329
Meta-chlorophenylpiperazine (mCPP)
cerebral blood flow in OCD and, 367
3-Methoxy-4-hydroxyphenylglycol (3-MHPG)
bupropion slow-release response in depression and, 629
plasma, in PTSD and major depressive disorder, 56
Metyrapone
neuroactive steroids in depression and, 912
Microglia
antimicrogial antibodies in Alzheimer's disease sera, 1359
Mirtazapine
overdose without complications, suicide attempts and, 925
Mitochondrial haplotypes
Alzheimer's disease and, 371
MN blood groups
major depression and, 361
Moclobemide
biological parameters in major depression and, 274
Molecular biology
serotonin receptors and, 1128
Monaminergic neurons
affective disorders and, 517
Monoamines
CSF, Prader-Willi syndrome and, 1321
Monkeys
social subordination stress, behavior, and central monoaminergic function in female cynomolgus monkeys, 882
Monoamine oxidase
biological parameters in major depression and, 274
Monoamine oxidase-A gene
major psychosis in Japanese subjects and, 922
Monoamine oxidase inhibitors
5-HT mechanisms in depression and OCD, 313
Montgomery-Asberg Depression Rating Scale
d-fenfluramine in major depression and, 555
SSRI discontinuation syndrome and, 77
Mood disorders
electrophysiology of prefrontal serotonin systems and, 1118
estrogen and serotonin, 798
global structural brain abnormalities and, 932-corr, 933-corr (response)
molecular biology of serotonin receptors and, 1128
parenteral clomipramine challnge in depressed adolescents, 562
seasonal, light exposure and, 622
serotonergic mechanisms and, 193
serotonin transporter and, 550
Morphometry
corpus callosum in male schizophrenics, 405
Motivation
anxiety and, 1248
Motor cortex
transcranial magnetic stimulation in PTSD and, 52
Motor learning
risperidone vs haloperidol in treatment-resistant schizophrenia, 726
Multifactorial models
competing models of positive symptoms in schizophrenia and, 107
Multiple-dose study
concurrent cocaine and alcohol use, 250
Muscarinic receptor sleep probes, major depression and, 21
Muscle spasm
spinally-induced, electroacupuncture and, 129

Na^+, K^+ adenosine triphosphatase
alpha subunit gene, bipolar disorder and, 47
in temporal cortex of bipolar individuals, 892
N-acetyl aspartate (NAA)
hippocampal, in unaffected siblings of schizophrenics, 941
schizophrenia and, 382
Naloxone
electroacupuncture and, 129
Nausea
SSRI discontinuation syndrome and, 77
Nefadozone
sleep and, 1-ed, 3
Negative symptoms
corpus callosum in male schizophrenics, 405
DRD4 gene and neuroleptic response in schizophrenia, 483
EEG coherence in neuroleptic-free schizophrenics and, 438
schizophrenia and, 115
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
NEO Personality Inventory
MRI correlates of depression in Alzheimer's disease and, 592
Neomycin phosphotransferase
serotonin receptors and, 163
Nervousness
SSRI discontinuation syndrome and, 77
Neural circuits
affective disorders and, 517
Neural tube defects
schizophrenia and homocysteine metabolism, 141
Neuroactive steroids
metyrapone in depression and, 912
Neurobehavioral measures
premorbid educational attainment in schizophrenia and, 739
Neurobiology
ADHD and, 951
anxiety disorders and, 1264, 1277, 1286, 1295, 1305
depersonalization and, 898
generalized anxiety disorder and, 1286
hippocampal N-acetyl aspartate in unaffected siblings of schizophrenics and, 941
social phobia and, 1277
Neurochemistry
schizophrenia and MRS, 382

Neurocircuitry
brain, panic disorder and, 1264
brain, underlying anxiety and fear, 1201, 1229, 1239, 1248
Neurocognitive deficits
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Neurodegenerations
progressive, after intracerebroventricular kainic acid in schizophrenia, 1143
Neuroelectric stimulation
electroacupuncture and, 129
Neuroendocrinology
parenteral clomipramine challnge in depressed adolescents, 562
plasma norepinephrine and 3-MHPG levels in PTSD, 56
serotonin and, 151
Neurofeedback treatment
pseudoseizure disorder and, 1196
Neuroleptic malignant syndrome
addition of carbamazepine to long-term neuroleptic treatment as cause of, 930
clinical and pharmacological risk factors for, 748
serum iron in, 499
specific treatment of, 378
Neuroleptics
addition of carbamazepine to long-term treatment with, neuroleptic malignant syndrome and, 930
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
DRD4 gene and neuroleptic response in schizophrenia, 483
EEG coherence in neuroleptic-free schizophrenics and, 438
hypofrontality in neuroleptic-naive and neuroleptic-free female schizophrenics, 787
nigrostriatial dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity, 765
P300 in schizophrenia and, 466
schizophrenia and MRS, 399
serum iron in catatonia and neuroleptic malignant syndrome, 499
striatal enlargement and, 675
tardive dyskinesia and serum iron indices, 493
Neurons
affective disorders and, 517
amino acid uptake sites in schizophrenia and, 423
biological parameters in major depression and, 274
cocaine withdrawal and serotonin function, 578
dopamine and serotonin metabolites in human CSF, 228
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
nonpyramidal CA2, in schizophrenia and depression, 88
novel therapeutic approaches beyond serotonin receptor, 324
serotonergic, and their projections, 145
serotonin in function of, and SSRIs in anorexia and bulimia nervosa, 825
Neuropeptides
affiliative behavior and, 207
Neurophysiology
EEG coherence in neuroleptic-free schizophrenics and, 438
Neuroplasticity
genetically-driven variation in serotonin uptake and, 179
Neuropsychology
ADHD in adulthood and, 260
Neurotoxins
genetically-driven variation in serotonin uptake and, 179
Neurotransmitters
amino acid uptake sites in schizophrenia and, 423
CSF serotonin and dopamine metabolites in alcoholisms and, 235, 243
glutamatergic, schizophrenia and, 667
major depression and, 1077
schizophrenia and, 382
Neurotrophins
antidepressant treatments in 21st century, 526
Neutral expressions
facial, gender differences in electrophysiological responses to facial stimuli, 281
New research series, 145
Nicotinic receptor desensitization
schizophrenia and, 98
Nigrostriatial dopaminergic activities
in dementia with Lewy bodies in relation to neuroleptic sensitivity, 765
Nipecotic acid
amino acid uptake sites in schizophrenia and, 423
N-methyl-D-aspartate (NMDA) antagonist model of schizophrenia
D-serine and, 1075
Nociception
electroacupuncture and, 129
Nomogram
dosing, patient variables and plasma clozapine concentrations, 733
Nonpyramidal cells
sector CA2, in schizophrenia and manic depression, 88
Noradrenergic antidepressants
adolescent and childhood depression, 336
β-Noradrenergic system
CCK4-induced panic and, 364
Norepinephrine
affective disorders and, 517
plasma, in PTSD and major depressive disorder, 56
No-saccade distractibility
antisaccade and no-saccade, chlorpromazine and lorazepam effects on, 709
Nuclear magnetic resonance (NMR)
schizophrenia and, 382, 399
Nutrition
schizophrenia and homocysteine metabolism, 141

Obsessive-compulsive disorder (OCD)
cerebral blood flow in, mCPP and, 367
intravenous clomipramine challenge and, 220
plasma melatonin and cortisol levels, 874
serotonergic mechanisms in, 193, 313

Occipital cortex
inositol in schizophrenia and, 428
Occupational attainment
ADHD in adulthood and, 260
Ocular motor systems
quantitative measurement of eye movements in schizophrenia and, 448
Oddball paradigm
high-density recording and topographic analysis in schizophrenia, 982
8-OH-DPAT
cocaine withdrawal and serotonin function, 578
Olanzapine
HIV and, 791
Onset
age of, assymetry and schizophrenia onset, 413
Operant responses
serotonin and neuropeptides in affiliative behaviors, 207
Opioids
electroacupuncture and, 129
Orienting response
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Overdose
mirtazapine, suicide attempts and, 925
Oxytocin
CSF levels, Prader-Willi syndrome and, 1349
plasma, ECT and, 610
serotonin and neuropeptides in affiliative behaviors, 207

P50 amplitude
dopamine and, 935-corr
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
P300 amplitude
schizophrenia and, 115, 466
P450 amplitude
gender differences in electrophysiological responses to facial stimuli, 281
Pain
electroacupuncture and, 129
threshold, and dissociative experiences and hypnotizability, 69
Panic
CCK4-induced, β-noradrenergic system and, 364
Panic disorder
alprazolam effect on loud tones in, 64
brain neurocircuitry and, 1264
epinephrine-induced panic and, 1017
regional cerebral metabolic asymmetries and, 998
sodium lactate and hypertonic sodium chloride induced equivalent panic incidence, panic symptoms, and hypernatremia in, 1007
Parenteral clomipramine challenge
depressed adolescents and, 562
Parents
fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
Parietal lobe
schizophrenia and, 115
Parkinson's disease
nigrostriatial dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity, 765
Paroxetine
biological parameters in major depression and, 274
elimination half-lives and, 75-ed
SSRI discontinuation syndrome and, 77
Patient variables
plasma clozapine concentrations and, 733
Patterning
of embryonic brain, serotonergic neurons and their projections, 145
Peak lateralization
P300 in schizophrenia and, 466
Pentylenetetrazole
deficient sensorimotor gating after seizures and, 290
Peptidergic neurons
affective disorders and, 517
Performance
assymetry and schizophrenia onset, 413
Peripheral markers
tardive dyskinesia and serum iron indices, 493
Peripheral serotonin measures
suicidal behavior and, 568
Perseverations
schizophrenia and, 459
Personality traits
MRI correlates of depression in Alzheimer's disease and, 592
repeated d-amphetamine challenge and, 1192
Phasic arousal
alprazolam in panic disorder and PTSD, 64
Phenotype
biological, genetics of schizophrenia and, 939
intermediate neurobiological, and hippocampal N-acetyl aspartate in unaffected siblings of schizophrenics, 941
serotonin receptors and, 163
Philips Gyroscan ACS II scanner
schizophrenia and MRS, 399
Phobia
social, neurobiology and, 1277
specific, etiology and pathophysiology of, 1295
Phosphatases
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Phosphate
schizophrenia and MRS, 399
Phosphatidyl inositol
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
Phosphocreatine
schizophrenia and MRS, 399
Phosphodiesterase
novel therapeutic approaches beyond serotonin receptor, 324

Phosphodiesters
schizophrenia and, 382, 399
Phosphoinositide-linked dopamine D1 receptor
repetitive jaw movements and, 1178
Phosphomonoesters
schizophrenia and, 382, 399
^{31}P-Phosphorus magnetic resonance spectroscopy (^{31}P-MRS)
schizophrenia and MRS, 399
Phosphorylation
regulated, trafficking of transporter proteins, 169
Phototherapy
seasonal mood variations and, 622
Physical abuse
serotonergic functioning in depressed abused children, 973
Physical activity
plasma melatonin and cortisol in obsessive-compulsive disroder and, 874
Pilocarpine/ipsaspirone sleep probe
major depression and, 21
Pindolol
5-HT mechanisms in depression and OCD, 313
Placebo
concurrent cocaine and alcohol use, 250
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
sertaline in depressed recently abstinent alcoholics and, 633
substitution, SSRI discontinuation syndrome and, 77
Plasma
bupropion slow-release response in depression and, 629
clozapine, patient variables and, 733
corticotropin-releasing factor in depressive disorders and, 15
dexamethasone window in Chinese depressives and, 648
fluphenazine, tardive dyskinesia and serum iron indices, 493
homovanillic acid, schizophrenia and, 488
melatonin and cortisol, obsessive-compulsive disorder and, 874
vasopressin and oxytocin, ECT effect on, 610
Plasma membrane
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Plasticity
genetically-driven variation in serotonin uptake and, 179
Platelet(s)
α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
monoamine oxidase, biological parameters in major depression and, 274
peripheral serotonin measures and suicidal behavior, 568
protein kinase C, depression and, 909
serotonin, biological parameters in major depression and, 274
Platelet storage granules
dopamine uptake by, in first degree relatives of Tourette's syndrome patients, 1166
Polarity-controlled study
shortened REM latency as psychobiological marker for psychotic depression, 1314
Polymerase chain reaction (PCR)
DRD4 gene and neuroleptic response in schizophrenia, 483
Polymorphisms
allelic association between bipolar disorder and *ATP1A3* gene, 47
dopaminergic receptor genes and manic depression, 644
DRD4 gene and neuroleptic response in schizophrenia, 483
genetically-driven variation in serotonin uptake and, 179
mitochondrial haplotypes in Alzheimer's disease and, 371
serotonin transporter in mood disorders and, 550
Polysomnography
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
sleep in Vietnam veterans with chronic PTSD, 1066
slow-wave sleep and ventricular size in schizophrenia and major depression, 121
Polyunsaturated fatty acids (PUFAs)
CSF serotonin and dopamine metabolites in alcoholism and, 235, 243
Positive and Negative Syndrome Scale
EEG coherence in neuroleptic-free schizophrenics and, 438
schizophrenia and, 115
Positive spikes
fourteen and six, ADHD and, 298
Positive symptoms
EEG coherence in neuroleptic-free schizophrenics and, 438
schizophrenia and, 107, 115
Positron emission tomography (PET)
cerebral activation during smooth pursuit and saccadic eye movements, 685
serotonin synapse in depression and, 534
Postmortem brain
amino acid uptake sites in schizophrenia and, 423
inositol in schizophrenia and, 428
Postmortem interval
nonpyramidal cells in sector CA2 in schizophrenia and manic depression, 88
"Poststroke" depression
secondary, serotonin synapse in depression and, 534
Postsynaptic mechanisms
5-HT mechanisms in depression and OCD, 313
Posttraumatic stress disorder (PTSD)
alprazolam effect on loud tones in, 64
chronic war-related, elevated awaking thresholds during sleep and, 1060
combat, plasma norepinephrine and 3-MHPG levels in, 56
event-related potentials to stimuli with emotional impact in, 1045
heart rate variability in, trauma-related reinder and, 1054
predicting development of, from acute response to traumatic event, 1305
psychophysiologic responsivity in, 1037
transcranial magnetic stimulation and, 52
in Vietnam veterans, experimental context and explicit threat cue effect on acoustic startle in, 1027
in Vietnam veterans, polysomnographic sleep and, 1066

Potentiation
fear-potentiated startle in adolescent offspring of parents with anxiety disorders, 990
Prader-Willi syndrome
CSF monoamines and, 1321
CSF oxytocin levels and, 1349
Predictability
epinephrine-induced panic and, 1017
Preference
assymetry and schizophrenia onset, 413
Prefrontal cortex
amino acid uptake sites in schizophrenia and, 423
Prefrontal dopamine metabolism
rebound hyperphagia induced by space restriction and, 1329
Prefrontal dorsolateral cortex
EEG coherence in neuroleptic-free schizophrenics and, 438
Prefrontal serotonin systems
electrophysiology and, 1118
Premenstrual dysphoric disorder (PMDD)
platelet α_2-adrenergic receptors and, 600
Premenstrual syndrome (PMS)
platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
saccadic eye velocity and, 755
Premorbid educational attainment
schizophrenia and, 739
Prenatal nutrition
schizophrenia and homocysteine metabolism, 141
Prepubertal psychiatric inpatients
peripheral serotonin measures and suicidal behavior, 568
Prepulse inhibition
deficient sensorimotor gating after seizures and, 290
Presynaptic mechanisms
5-HT mechanisms in depression and OCD, 313
Presynaptic serotonin transporters (SERTS)
antidepressant-sensitive, trafficking of, 169
Principle component analysis
schizophrenia and, 115
Probanthine
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Progressive behavioral response
repeated d-amphetamine challange and, 1171
Prolactin
cocaine withdrawal and serotonin function, 578
d-fenfluramine in major depression and, 555
Propranolol
β-noradrenergic system in CCK-induced panic and, 364
Protein kinase C (PKC)
platelet, depression and, 909
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Pseudoseizure disorder
neurofeedback treatment and, 1196
Psychoactive substance use disorder (PSUD)
ADHD and, 269
Psychobiological markers
psychotic depression and, 1314
Psychological assessment
transcranial magnetic stimulation in PTSD and, 52
Psychopathology
schizophrenia and, 115
Psychophysiology
alprazolam in panic disorder and PTSD, 64
PTSD and, 1037
Psychosis
affective, symptom correlates of attentional improvement after hospitalization for first episode, 784
apolipoprotein E genotypes in elderly population and, 139
competing models of positive symptoms in schizophrenia and, 107
deficient sensorimotor gating after seizures and, 290
electrophysiology of prefrontal serotonin systems and, 1118
molecular biology of serotonin receptors in, 1128
shortened REM latency as psychobiological marker for psychotic depression, 1314
Psychosocial treatments
ADHD and stress response, 72
Putamen
mCPP effects on cerebral blood flow in OCD and, 367

Quantitative measurement
of eye movements, schizophrenia and, 448

Racial differences
peripheral serotonin measures and suicidal behavior, 568
Raclopride
MDL 100,907, 508
Radiotracers
serotonin synapse in depression and, 534
Randomized clinical trials
SSRI discontinuation syndrome and, 77
Rapid eye movement (REM)
latency, as psychobiological marker for psychotic depression, 1314
latency, slow-wave sleep and ventricular size in schizophrenia and major depression, 121
nefadozone and fluoxetine effects on sleep and, 1-ed, 3
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Reaction time
risperidone vs haloperidol in treatment-resistant schizophrenia, 726
slowed, brain abnormalities in elderly depressives and, 34
Rebound hyperphagia
space restriction-induced, prefrontal and striatal dopamine metabolism during, 1334
Receptors
antidepressant treatments in 21st century, 526
cocaine withdrawal and serotonin function, 578
dopaminergic receptor genes and manic depression, 644
DRD4 gene and neuroleptic response in schizophrenia and, 483
intracellular Ca^{++} in frontal cortex and, 617
5-HT mechanisms in depression and OCD, 313
molecular biology of serotonin receptors, 1128

nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
phosphoinositide-linked dopmaine D1 receptor and repetitive jaw movements, 1178
platelet α_2-adrenergic receptors in premenstrual dysphoric disorder and, 600
raclopride and MDL 100,907, 508
serotonin, novel strategies to probe functions of, 163
serotonin, novel therapeutic approaches beyond, 324
serotonin synapse in depression and, 534
Reciprocal interaction model
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Recurrent depression
long-term maintenance treatment of, 348
Regional cerebral blood blow
mCPP effects on cerebral blood flow in OCD and, 367
Regional cerebral metabolic asymmetries
panic disorder and, 998
Regulated phosphorylation
trafficking of antidepressant-sensitive serotonin transporter proteins and, 169
Reminder
trauma-related, PTSD and, 1054
Remission
DRD4 gene and neuroleptic response in schizophrenia, 483
Remoxipride
P300 in schizophrenia and, 466
Repeat expansion detection method
and CAG/CTG repeat size in schizophrenia and bipolar disorder, 1160
Repetitive jaw movements
phosphoinositide-linked dopamine D1 receptor and, 1178
Residual schizophrenia
quantitative measurement of eye movements in, 448
Response inhibition
ADHD and stress response, 72
Resting issue
hypofrontality and, 787
Restriction fragment length polymorphisms (RFLPs)
dopaminergic receptor genes and manic depression, 644
mitochondrial haplotypes in Alzheimer's disease and, 371
Risperidone
HIV and, 791
treatment-resistant schizophrenia and, 726
Rorschach inkblot test
skin conductance hyporesponsivity and perseverations in schizophrenia, 459

Saccades
anticipatory, during smooth pursuit eye movements in schizophrenia, 690
distractibility and, chlorpromazine and lorazepam effects on, 709
voluntary, quantitative measurement of eye movements in schizophrenia and, 448
Saccadic eye movements
cerebral activation during, positron emission tomography and, 685
Saccadic eye velocity
premenstrual syndroem and, 755
Sad expressions
facial, gender differences in electrophysiological responses to facial stimuli, 281
Sadness
parenteral clomipramine challnge in depressed adolescents, 562
Saline
cocaine withdrawal and serotonin function, 578
Salivary sampling
ADHD and stress response, 72
Scale for the Assessment of Negative Symptoms
skin conductance hyporesponsivity and perseverations in schizophrenia, 459
Scale for the Assessment of Positive Symptoms
competing models of positive symptoms in schizophrenia and, 107
Schizoaffective disorder
plasma homovanillic acid in, 488
Schizophrenia
amino acid uptake sites in, 423
anticipatory saccades during smooth pursuit eye movements and familial transmission of, 690
asymmetry and onset of, 413
auditory oddball event-related potential in, high-density recording and topographic analysis, 982
auditory oddball paradigm in, 115
biological phenotypes and genetics in, 939
CA2 in, 88
CAG/CTG repeat size in, repeat expansion detection method and, 1160
clinical deficits in, 667
clozapine in, 475
corpus callosum in male patients, 405
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
deficient sensorimotor gating after seizures and, 290
DRD4 gene and neuroleptic response in, 483
EEG coherence in, 438
electrophysiology of prefrontal serotonin systems in, 1118
eye tracking abnormalities in, 698
factor analysis in, 115
frontal eye fields in, 698
genetically-driven variation in serotonin uptake and, 179
glutamatergic neurotransmission in, 667
haloperidol in, 475, 726
homocysteine metabolism in, 141
homovanillic acid in, 488
inositol in, 428
magnetic resonance spectroscopy and, 382, 399
manual dexterity in, 726
MN blood groups in, 361
molecular biology of serotonin receptors in, 1128
motor learning in, 726
negative symptoms in, 115
nicotinic receptor desensitization in, 98

P300 in, 466
positive symptoms in, 107, 115
premorbid educational attainment in, 739
progressive neurodegenerations after intracerebroventricular kainic acid in, 1143
quantitative measurement of eye movements in, 448
reaction time in, 726
risperidone in, 726
sensory gating deficits in, 98
D-serine added to antipsychotics for treatment of, 1081
serotonin in, 1079, 1099
skin conductance hyporesponsivity and perseverations in, 459
slow-wave sleep and ventricular size in, 121
SPECT study of hypofrontality in neuroleptic-naive and neuroleptic-free female schizophrenics, 787
structural deficits in, 667
tardive dyskinesia and serum iron indices in, 493
temporal horn enlargement in, 418
thought disorder factor in, 115
Schneiderian delusions
competing models of positive symptoms in schizophrenia and, 107
School
ADHD in adulthood and, 260
Seasonal affective disorder (SAD)
seasonal mood variations and light exposure, 622
Seasonal mood variations
light exposure and, 622
Second messengers
inositol in schizophrenia and, 428
novel therapeutic approaches beyond serotonin receptor, 324
Seizures
deficient sensorimotor, 290
Selective serotonin reuptake inhibitors (SSRIs)
antidysphoric/antianxiolytic profiles, 865
anxiety spectrum and, 812
child and adolescent depression, 336
clomipramine and depersonalization disorder, 302
discontinuation syndrome and, 77
elimination half-lives and, 75-ed
5-HT mechanisms in depression and OCD, 313
nefadozone and fluoxetine effects on sleep and, 1-ed, 3
novel therapeutic approaches beyond serotonin receptor, 324
risks and benefits of combining SSRIs with other serotonergic drugs, 341
serotonin neuronal function in anorexia and bulimia nervosa, 825
sexual dysfunction and, 374-corr
3α,5α-tetrahydroprogesterone and, 865
Semantic encoding
for verbal memory, ADHD in adulthood and, 260
Sensitization
progressive behavioral response to repeated d-amphetamine challenge and, 1171
serotonergic mechanisms and, 193
Sensorimotor gating
deficient, after seizures, 290
Sensory gating deficits
schizophrenia and, 98
Separation
serotonin and neuropeptides in affiliative behaviors, 207
D-Serine
antipsychotics with, schizophrenia and, 1081
N-methyl-D-aspartate antagonist model of schizophrenia and-ed, 1075
Serotonergic neurons
and their projections, 145
Serotonergic synergism
risks and benefits of combining SSRIs with other serotonergic drugs, 341
Serotonin
activity marker, fenfluramine challenge test and, 918
adolescent and childhood depression, 336
affective disorders and, 517
affiliative behavior and, 207
antipsychotic drug effects in schizophrenia and, 1099
anxiety disorders and, 193
biological parameters in major depression and, 274
cocaine withdrawal and, 578
CSF metabolites, predicted by essential fatty acids in alcoholism, 235, 243
depressed abused children and, 973
estrogen interactions with, affective regulation and, 839
feeding and affect regulation, 795-ed
d-fenfluramine in major depression and, 555
hypothalamic, in eating behavior, meal size, and body weight, 851
illness progression and, 193
intracellular Ca^{++} in frontal cortex and, 617
kindling and, 193
mechanisms in depression and OCD, 313
metabolites, human CSF and, 228
mood disturbance and, 798
neuronal function, and SSRIs in anorexia and bulimia nervosa, 825
obsessive-compulsive disorder and, 193
overview, 309-ed
peripheral measures, suicidal behavior and, 568
prefrontal systems, electrophysiology and, 1118
receptors, molecular biology and, 1128
receptors, novel strategies to probe functions of, 163, 324
reuptake, regulation of, 169
schizophrenia and, 1079
sensitization and, 193
spectrum of behaviors influenced by, 151
synapse imaging in depression, 534
Serotonin $_{1A}$
receptor sleep probes, major depression and, 21
Serotonin$_{2A}$
antipsychoticlike action and, 508

Serotonin syndrome
risks and benefits of combining SSRIs with other serotonergic drugs, 341
Serotonin transporter
genetically-driven variation in serotonin uptake and, 179
in major depression, imaging and, 1090
mood disorder and, 550
serotonin synapse in depression and, 534
Sertraline
depressed recently abstinent alcoholics and, 633
elimination half-lives and, 75-ed
SSRI discontinuation syndrome and, 77
Serum
iron, in catatonia and neuroleptic malignant syndrome, 499
iron, tardive dyskinesia and, 493
Severity models
competing models of positive symptoms in schizophrenia and, 107
Sexual abuse
serotonergic functioning in depressed abused children, 973
Sexual behavior
serotonin and neuropeptides in affiliative behaviors, 207
Sexual dysfunction
SSRIs and, 374-corr
Siblings
of schizophrenics, hippocampal N-acetyl aspartate in, 941
Sigma power
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Signal transduction
CSF inositol monophosphatase in depression and neuroleptic-treated schizophrenia, 433
intracellular, novel therapeutic approaches beyond serotonin receptor, 324
Single photon emission computed tomography (SPECT)
hypofrontality in neuroleptic-naive and neuroleptic-free female schizophrenics, 787
mCPP effects on cerebral blood flow in OCD and, 367
serotonin synapse in depression and, 534
serotonin transporter in major depression and, 1090
Skin conductance
alprazolam in panic disorder and PTSD, 64
hyporesponsivity, schizophrenia and, 459
Skin patch electrodes
electroacupuncture and, 129
SLC6A4 locus
serotonin transporter in mood disorders and, 550
Sleep
elevated awaking thresholds during, in chronic war-related PTSD, 1060
nefadozone and fluoxetine effects on, 1-ed, 3
nicotinic receptor desensitization and sensory gating deficits in schizophrenia, 98
pilocarpine/ipsaspirone sleep probe in major depression and, 21
polysomonographic, in Vietnam veterans with chronic PTSD, 1066
seasonal mood variations and light exposure, 622
serotonin and neuropeptides in affiliative behaviors, 207
Slow waves
fourteen and six positive spikes and ADHD, 298
Slow wave sleep
pilocarpine/ipsaspirone sleep probe in major depression and, 21
ventricular size and, 121
Smooth pursuit eye movements
anticipatory saccades during, familial transmission of schizophrenia and, 690
cerebral activation during, positron emission tomography and, 685
quantitative measurement of eye movements in schizophrenia and, 448
Social interaction
serotonin and neuropeptides in affiliative behaviors, 207
Social phobia
neurobiological perspectives and, 1277
Social subordination stress
female cynomolgus monkeys and, 882
Socioeconomic status
corpus callosum in male schizophrenics, 405
Sodium chloride
hypertonic, panic disorder and, 1007
Sodium lactate
panic disorder and, 1007
Somatization
fourteen and six positive spikes and ADHD, 298
hypnotizability, pain threshold, and dissociative experiences, 69
transcranial magnetic stimulation in PTSD and, 52
Space restriction
rebound hyperphagia induced by, prefrontal and striatal dopamine metabolism during, 1329
Specific phobia
etiology and pathophysiology of, 1295
Spectral analysis
pilocarpine/ipsaspirone sleep probe in major depression and, 21
Sprague-Dawley rats
raclopride and MDL 100,907, 508
Stage 3/4 sleep
nefadozone and fluoxetine effects on, 3
Startle
acoustic, deficient sensorimotor gating after seizures and, 290
acoustic, experimental context and explicit threat cue effect on in combat-related PTSD, 1027
fear-potentiated, in adolescent offspring of patents with anxiety disorders, 990
serotonin and neuropeptides in affiliative behaviors, 207
Tourette's syndrome and, 935-corr
Steroids
neuroactive, metyrapone in depression and, 912
Stratum pyramidale
nonpyramidal cells in sector CA2 in schizophrenia and manic depression, 88

Stress
ADHD and stress response, 72
antidepressant treatments in 21st century, 526
novel therapeutic approaches beyond serotonin receptor, 324
social subordination, female cynomolgus monkeys and, 882
transcranial magnetic stimulation in PTSD and, 52
Stria
amygdala-stria terminalis model for anxiety disorders and, 1204
Striatal dopamine metabolism
rebound hyperphagia induced by space restriction and, 1329
Striatum
enlargement, neuroleptics and, 675
Stroke
electroacupuncture and, 129
Stroop paradigm
emotional counting, functional MRI imaging probe and, 1219
Subcortical lesions
brain abnormalities in elderly depressives and, 34
Subordination
female cynomolgus monkeys and, 882
Substance abuse
ADHD and, 269
biological markers of heavy drinking and, 638
cocaine withdrawal and serotonin function, 578
concurrent cocaine and alcohol use, 250
genetically-driven variation in serotonin uptake and, 179
Suggestibility
hypnotizability, pain threshold, and dissociative experiences, 69
Suicide
essential fatty acids predict CSF serotonin and dopamine metabolites in alcoholism, 235, 243
inositol in schizophrenia and, 428
Suicide attempts
with mirtazapine overdose without complications, 925
peripheral serotonin measures and, 568
Summer
seasonal mood variations and light exposure, 622
Superior temporal gyrus
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Suspiciousness
pretreatment plasma HVA in schizophrenia and schizoaffective disorder, 488
Symptom Check List-90
transcranial magnetic stimulation in PTSD and, 52
Symptom provocation
mCPP effects on cerebral blood flow in OCD and, 367
The Symptom Questionnaire
SSRI discontinuation syndrome and, 77
Synaptosomes
intracellular Ca^{++} in frontal cortex and, 617
Synergism
serotonergic, risks and benefits of combining SSRIs with other serotonergic drugs, 341

Tandem repeats
DRD4 gene and neuroleptic response in schizophrenia, 483
Tardive dyskinesia
serum iron indices and, 493
Tc-hexamethyl-propyleneamineoxime SPECT ^{99m}
mCPP effects on cerebral blood flow in OCD and, 367
Temperature
axillary, plasma melatonin and cortisol in obsessive-compulsive disroder and, 874
Temperoparietal regions
schizophrenia and, 115
Temporal cortex
in bipolar disorder, alpha2 isoform of Na,K-adenosine triphosphatase and, 892
Temporal dynamics
tics in Gilles de la Tourette syndrome and, 1337
Temporal horns
enlargement of, in schizophrenia and bipolar disorder, 418
Temporal lobes
amino acid uptake sites in schizophrenia and, 423
assymetry and schizophrenia onset, 413
schizophrenia and, 382
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Tetracycline
serotonin receptors and, 163
3α5α-Tetrahydroprogesterone
SSRIs and, 865
Thalamus
mCPP effects on cerebral blood flow in OCD and, 367
Third cerebral ventricle
brain abnormalities in elderly depressives and, 34
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Thought disorder factor
schizophrenia and, 115
Threat cues
explicit, effects of on acoustic startle in Vietnam veterans with PTSD, 1027
Tics
temporal dynamics of, Tourette's syndrome and, 1337
Time domain measures
heart period variability and depression, 304
Tobacco
biological markers of heavy drinking and, 638
Topographic analysis
auditory oddball event-related potential in schizophrenia and, 982
P300 in schizophrenia and, 466
Total iron binding capacity
tardive dyskinesia and serum iron indices, 493
Tourette's syndrome
first degree relatives of patients, dopamine uptake by platelet storage granules in, 1166
startle and, 935-corr
temporal dynamics of tics and, 1342

Toxicity
concurrent cocaine and alcohol use, 250
Transcranial magnetic stimulation (TMS)
PTSD and, 52
Transgenes
genetically-driven variation in serotonin uptake and, 179
Trauma
acute response to, predicting PTSD development and, 1305
Trauma-related reminder
in PTSD, heart rate variability and, 1054
Trauma specificity
PTSD and, 1037
Tricyclic antidepressants
adolescent and childhood depression, 336
5-HT mechanisms in depression and OCD, 313
Trimethylsilyl derivatives
inositol in schizophrenia and, 428
trk receptors
antidepressant treatments in 21st century, 526
Tryptophan
whole blood, peripheral serotonin measures and suicidal behavior, 568
Tryptophan hydroxylase
serotonin synapse in depression and, 534

Ultradian rhythms
plasma norepinephrine and 3-MHPG levels in PTSD, 56
Unaffected siblings
of schizophrenics, hippocampal N-acetyl aspartate in, 941
Unipolar depression
recurrent major, long-term maintenance treatment of, 348
Uptake sites
amino acid, schizophrenia and, 423
Urine
biopterins, biological parameters in major depression and, 274

Vasopressin
plasma, ECT and, 610
serotonin and neuropeptides in affiliative behaviors, 207
Ventral hindbrain
serotonergic neurons and their projections, 145
Ventricular-brain ratio
brain abnormalities in elderly depressives and, 34
slow-wave sleep and, in schizophrenia and major depression, 121
Ventricular enlargement
temporal horn enlargement in schizophrenia and bipolar disorder, 418
Verbal memory
ADHD in adulthood and, 260
Vietnam veterans
with PTSD, experimental context and explicit threat cues effects on acoustic startle in, 1027
Vigilance
ADHD in adulthood and, 260
Viloxazine
biological parameters in major depression and, 274
Violence
impulsive, essential fatty acids predict CSF serotonin and dopamine metabolites in alcoholism, 235, 243
Visual attention
in schizophrenia, processing of auditory stimuli and, 1151
Visual distractors
quantitative measurement of eye movements in schizophrenia and, 448
Volume selective technique
schizophrenia and MRS, 399
Voluntary saccades
quantitative measurement of eye movements in schizophrenia and, 448

Well-being
perception of, concurrent cocaine and alcohol use, 250
White matter
lesions, brain abnormalities in elderly depressives and, 34
MRI correlates of depression in Alzheimer's disease and, 592
Whole blood tryptophan
peripheral serotonin measures and suicidal behavior, 568
Window
dexamethasone, Chinese depressives and, 648
Winter
seasonal mood variations and light exposure, 622
Withdrawal
cocaine, serotonin and, 578

Zoology
social phobia and, 1277